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ABBREVIATIONS 
 
5HT – serotonin 
ACS – acute coronary syndrome 
ADP – adenosine-diphosphate 
ApoE – apolipoprotein E 
ARC – Academic Research Consortium 
ASA – acetylsalicylic-acid 
ATP – adenosine-triphosphate 
AUC – area under the curve 
CAD – coronary artery disease 
CD40L – cluster of differentiation 40 ligand 
CI – confidence interval 
COX – cyclooxygenase 
CRP – C reactive protein 
CYP – cytochrome P450 
DAPT – dual antiplatelet therapy 
ELISA – enzyme linked immunosorbent assay 
EP1-4 – prostaglandin E2 receptor family 
ESC – European Society of Cardiology 
FXIII – factor XIII 
GP – glycoprotein 
HR – hazard ratio 
IP – prostacyclin (prostaglandin I2) receptor  
IQR – interquartile range 
LDL – low density lipoprotein 
LOWESS – locally weighted scatterplot smoothing 
LTA – light transmission aggregometry 
MEA – multiple electrode aggregometry 
NO – nitric-oxide 
OR – odds ratio 
PAD – peripheral artery disease 
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PAI1 – plasminogen activator inhibitor 1 
PAR – protease-activated receptor 
PCI – percutaneous coronary intervention 
PDE - phosphodiesterase 
PDGF – platelet derived growth factor 
PF4 – platelet factor 4 
PF – platelet function 
PGE1 – prostaglandin E1 
PI3K - phosphatidylinositol-3 kinase 
PKA – protein kinase A 
PKC – protein kinase C 
PLA2 – phospholipase A2 
PLT - platelet 
PPP – platelet poor plasma 
PRP – platelet rich plasma 
PsNR – pseudo non-responder 
RCT – randomized controlled trial 
RNR – real non-responder 
SCAD – stable coronary artery disease 
TIA – transient ischemic attack 
TIMI – thrombolysis in myocardial infarction 
TP – thromboxane protein 
TRAP – thrombin receptor activating peptide 
TXA2 – thromboxane A2 
TXB2 – thromboxane B2 
U - unit 
VASP – vasodilator-stimulated phosphoprotein 
vWF – von Willebrand factor 
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1. INTRODUCTION 
Cardiovascular disease is the principal cause of death in the western societies. Clinical 
manifestations of coronary artery disease include stable coronary artery disease and 
acute coronary syndromes. Revascularization by percutaneous coronary intervention 
became one of the most important therapeutic possibilities in both forms of ischemic 
heart disease. To maximize its clinical benefit, many procedural and pharmaceutical 
improvements have been carried out in the past two decades, of which introduction of 
dual antiplatelet therapy with aspirin and clopidogrel to prevent thrombotic events after 
percutaneous coronary intervention proved to be essential. Recently, novel, more potent 
antiplatelet agents turned up and the clinical utility of platelet function testing and 
tailored antiplatelet therapy became an extensively researched field in cardiology.  
1.1. Role of platelets in ischemic heart disease 
1.1.1. Central pathophysiological role of platelets in atherosclerosis 
Atherosclerosis, the disease of the vascular intima characterized by intimal lipid 
accumulation and plaque formation, affects principally the large and medium-sized 
elastic and muscular arteries. Atherogenesis starts with the loss of intact endothelial 
function due to several different noxae [1]. In its physiological state, endothelium is a 
substantive organ ensuring normal blood flow conditions, trans-endothelial transports 
and equilibrium of vasoactive substances and hemostasis. Different forms of endothelial 
injury increase its adhesiveness, permeability and procoagulant properties and also, 
result in intensified platelet adherence and aggregation [1]. Platelets play an important 
role in the initiation of atherosclerosis via several surface glycoproteins (e.g. GPIbα, 
GPIIb/IIIa, and β3 integrin) which enables platelet “rolling” even on the structurally 
intact endothelium, then a firm platelet-vessel wall interaction followed by leukocyte 
accretion and release of several mediators [2-4]. The earliest type of atherosclerotic 
lesion is the fatty streak, which is a pure inflammatory lesion [5]. Several data supports 
how platelets contribute to vascular inflammation via interactions with inflammatory 
cells. Platelet activation results in expression of several inflammatory receptors, 
enrolment of leukocytes and monocytes, formation of platelet-leukocyte aggregates [6-
11] and release of active biomolecules and chemokines from the platelet granules [12]. 
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Permanent activation of inflammatory cells and platelets results in smooth-muscle cell 
migration into the intima and fatty streaks progress into intermediate and advanced 
lesions, leading to wall thickening and lumen narrowing of the arteries. With further 
progression, atherosclerotic lesions tend to form a fibrous cap (mediated by distinct 
growths factors and decreased connective-tissue degradation) [1] covering a necrotic 
core containing leukocytes, lipid, and debris.  
Stable advanced lesions usually have uniformly dense fibrous caps. In contrast, 
plaques may become unstable with thinning of the fibrous cap at the shoulder region of 
the atheroma due to permanent activation of macrophages releasing proteolytic enzymes 
[13]. The most dangerous consequences of unstable plaques are plaque rupture 
occurring at thinning of the fibrous cap and plaque erosion [14,15] followed by intra 
plaque hemorrhage, activation of platelets and the coagulation cascade, resulting in 
thrombus formation and occlusion of the artery. Active disruption is related to extrinsic 
factors (e.g. rheological circumstances) and passive disruption is due to several intrinsic 
factors (large lipid core, high cholesteryl ester content, high density of macrophages and 
low density of smooth muscle cells, narrowed fibrous cap and high tissue factor 
concentration [16]) defining the stable or unstable characteristics of the plaque. The 
potentially dangerous lesions are often non occlusive and thus are difficult to diagnose 
by angiography. The other mechanism of plaque injury is erosion, which occurs mainly 
in women [17] and is caused by endothelial denudation. Causative role of erosion can 
be as high as 40% of acute coronary syndromes and 25% of myocardial infarctions [18].  
 
1.1.2. Platelets in atherothrombosis: adhesion, activation and aggregation 
Platelets play central roles in physiologic and pathologic processes of primary and 
secondary hemostasis. Primary hemostasis is the rapid formation of a platelet plug at the 
injured/alternated vessel wall. Secondary hemostasis is the parallel activation of the 
coagulation cascade resulting in formation of a fibrin strand further strengthening the 
primary thrombus. The initial step in primary hemostasis is the adhesion of platelets to 
the exposed subendothelial matrix with surface glycoproteins. The adhesive process can 
be initiated via the collagen receptor GPIa/IIa complex, but under high shear conditions 
platelet adhesion is mediated by the soluble plasma protein von Willebrand factor 
through the GPIb/V/IX complex [19]. Primary adhesion activates intracellular signaling 
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pathways (outside-in signaling) leading to intracellular Ca2+ elevation and activation of 
intracellular kinases (e.g. PKA, PKC, PI3K, see Figure 1) [20]. This results in 
cytoskeletal and membrane rearrangement, morphological changes (shape change), 
secretion of several mediators (e.g. TXA2) and also, exhaustion of the α-granules 
(fibrinogen, plasminogen, fibronectin, vitronectin, thrombospondin, PF4, PAI1, and 
PDGF) and dense granules (e.g. ADP, ATP, serotonin, epinephrine, Ca2+). The 
consequent conformational changes of certain membrane glycoproteins (inside-out 
signaling) lead to exposure of binding sites and enables interaction of soluble adhesive 
plasma proteins fibrinogen and vWF with the membrane GPIIb/IIIa complex [21]. This 
results in further conformational change of the receptor with subsequent activation of 
several intracellular kinases leading to bridge formation between the adjacent platelets 
leading to formation of aggregates [22]. After initial activation, amplification loops 
represented by accelerated TXA2 and ADP production ensure recruitment and rapid 
formation of platelet rich thrombi. The most important platelet activating receptors are 
thrombin receptors (PAR1 and PAR4), purinergic receptors (P2X1, P2Y1 and P2Y12), 
collagen receptors (GPIb/V/IX, GPIa/IIa, and GPVI), TXA2 receptors (TP), 5HT2A 
receptors, α2-adrenergic receptors, and the prostaglandin E2 receptors (EP1-4) while the 
most important inhibitory receptors are the prostacyclin (PGI2) and NO receptors. The 
main platelet activating receptors and intracellular signaling pathways are summarized 
in Figure 1. 
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Figure 1. Main platelet activating receptors and pathways. Black arrows indicate activation, red 
arrows denote inhibition. Bent arrows indicate transformation/metabolization. After activation of a 
stimulatory surface receptor, one of the most important consequences is the elevation of intracellular Ca2+ 
level, activation of intracellular kinases (eg. PKA, PKC, PI3K) and decrease of intracellular cAMP (which 
enhances the Ca2+ uptake into the sarcoplasmic reticulum). These processes result in shape change, 
degranulation, membrane rearrangement and exposure of hidden binding sites of certain membrane 
glycoproteins enabling the platelets to anchor to the subendothelial collagen and adhere to adjacent 
platelets. The purinergic P2X1 and P2Y1 receptors mediate mainly the initiation of platelet activation by 
increasing the intracellular Ca2+ level resulting in shape change of the platelet. The P2Y12 receptor, 
activated by ADP, represents the major amplification loop of platelet activation leading to the formation 
of a stable platelet aggregate. 5HT2A: serotonin receptor, AA: arachidonic-acid, AMP: adenosine-
monophosphate, cAMP: cyclic-adenosine-monophosphate, COX: cyclooxygenase, EP: prostaglandin 
receptor, Gi (inhibitory)-, Gq- and Gs (stimulatory): different subtypes of the G protein according to the α 
subunit, Gp: glycoprotein, IP3: inositol trisphosphate, PAR: protease activated receptor, PDE: 
phosphodiesterase, PI3K: phosphatidylinositol-3-kinase, PKA: protein kinase A, PKC: protein kinase C, 
PLC: phospholipase C, P2X1, P2Y1 and P2Y12: subtypes of the purinergic receptors, TXA2: thromboxane 
A2, VASP: vasodilator-stimulated phosphoprotein, VASP-P: phosphorylation of vasodilator-stimulated 
phosphoprotein 
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1.2. Antiplatelet therapy in coronary artery disease  
1.2.1. Antiplatelet agents 
1.2.1.1. COX1 inhibitors  
Synthetized in the late nineteenth century, aspirin (acetylsalicylic-acid) is the oldest 
antiplatelet drug [23]. Its platelet inhibitory effect was discovered in the mid-1960s, and 
since then it has become the cornerstone of antiplatelet therapy in primary and 
secondary prevention of ischemic heart disease [24,25]. ASA covalently binds to and 
irreversibly inhibits the cyclooxygenase enzymes, exerting 50-100 fold higher affinity 
for the COX1 than to the COX2 enzyme [26]. COX inhibition leads to impaired TXA2 
synthesis from arachidonic-acid, which is released from the membrane constituent 
phospholipids by PLA2 following cell activation [23]. As TXA2 is a potent 
vasoconstrictor and platelet activating agent via the platelet TP receptor, inhibiting this 
pathway profoundly decreases platelet activity and aggregability. Impaired platelet 
function caused by ASA is obtained during the life span of the platelet (7-10 days). 
Though aspirin has a short plasma half-life (15-20 minutes), constant administration of 
low dose aspirin results in continuous platelet inhibition due to low daily platelet turn-
over [27]. Therefore, the platelet inhibitory effect of aspirin is not linearly dose-
dependent in contrast to its gastrointestinal toxicity. ASA has several COX independent 
antithrombotic effects as well, such as inhibition of thrombin generation [28] and 
enhancement of fibrinolysis [29], contributing to the favorable therapeutic effect of 
aspirin. The mechanism of action of the currently available and developmental 
antiplatelet agents are summarized in Figure 3. 
1.2.1.2. P2Y12 receptor inhibitors  
According to our current understanding, the P2Y12 receptor has a central role in almost 
all platelet functions, being responsible for the major amplification loop of platelet 
activation and thus is a very promising target for antithrombotic drugs. Platelet 
aggregatory response provoked by ADP is initiated by the P2Y1 receptor resulting in 
shape change and initial activation and aggregation of adjacent platelets. P2Y12 receptor 
is liable for the ADP-dependent amplification of secretion, procoagulant activity, 
aggregation and finally for stabilization of the platelet thrombus [30]. Since the results 
of early studies with ticlopidine [31] and those of the large clinical studies with 
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clopidogrel [32,33], additional use of a P2Y12 blocking agent to ASA has been used to 
prevent ischemic events after percutaneous coronary intervention . 
Thienopyridines. Thienopyridines covalently bind to the P2Y12 receptor leading to 
irreversible inhibition of platelet function for the life span of the platelet (7-10 days). 
The first generation ticlopidine was soon replaced by the second generation clopidogrel 
due to ticlopidine’s adverse side effects (i.e neutropenia and thrombotic 
thrombocytopenic purpura). Clopidogrel’s favorable therapeutic effect is attributed to its 
antiplatelet and anti-inflammatory profile. Beside irreversible P2Y12 blockade, 
clopidogrel has also been reported to attenuate platelet–leukocyte aggregate formation 
[34], periprocedural increase of CRP levels [35], and to reduce P-selectin and CD40L 
expression [36] and the rate of thrombin formation [37]. However, clopidogrel has wide 
inter-individual efficacy in terms of platelet inhibition. The potential causative roles in 
its background included pharmacokinetic, pharmacodynamic, clinical, genetic and 
cellular mechanisms as well as the patient’s compliance [38] (see also below). Recently, 
the third generation, more potent prasugrel has been introduced in the clinical practice 
[39,40]. Prasugrel has a more rapid onset of action and a more extent platelet inhibitory 
effect and proved to be superior to clopidogrel in large clinical studies, though at a price 
of increased bleeding risk [41]. All thienopyridines are prodrugs and require 
metabolization via the hepatic CYP enzymes to pass into its biologically active 
metabolite. The activating steps and the involved hepatic enzymes somewhat differ at 
each drug, resulting in different pharmacokinetic and -dynamic features, and explains 
the distinct drug-drug interference profile of the compounds (Figure 2, Table 1). 
 Nucleotide/nucleoside analogues. These drugs are active agents not requiring metabolic 
transformation, thus having immediate antiplatelet effect upon intravenous 
administration or intestinal absorption. Ticagrelor is an orally administered reversible 
allosteric inhibitor of the P2Y12 receptor. Ticagrelor proved to be favorable compared to 
clopidogrel in large clinical studies exerting a more expressed and faster antiplatelet 
effect [42]. Cangrelor recently got approval based on the results of the CHAMPION-
PHOENIX study, where it significantly reduced the rate of ischemic events during PCI, 
with no significant increase in severe bleeding [43]. This intravenously administered 
ATP derivative is used to achieve immediate and complete platelet inhibition before 
DOI:10.14753/SE.2016.1919
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PCI and may be used in patients who are unable to swallow and/or in bridging therapy 
before surgery in patients requiring P2Y12 inhibitor therapy [44]. After cessation of its 
administration normal platelet function is restored within 1 hour [43,44]. 
 
Figure 2. Metabolization of the P2Y12 inhibitors. After absorption, ticlopidine undergoes extensive 
metabolization by the hepatic CYP enzymes. The active metabolite is formed in a two-step oxidation, 
through the intermediate 2-oxo-ticlopidine [45]. The CYP enzymes involved in the second oxidation step 
are not identified. Clopidogrel, after intestinal absorption, is extensively hydrolyzed by plasma esterases 
into an inactive compound. The remaining clopidogrel fraction undergoes a two-step oxidation process in 
the liver to turn into its bioactive form via the intermediate 2-oxo-clopidogrel [45]. Prasugrel is also a 
pro-drug, but its activation process is started by plasma esterases and includes only one CYP-dependent 
step, which importantly, is mediated mainly by the intestinal CYP3A enzymes (*) [45]. This explains the 
lack of drug-drug interactions reported with the use of prasugrel. Ticagrelor is an ab ovo active agent, 
though 30-40% of its action is linked to its active, bioequivalent metabolite transformed by hepatic CYP 
enzymes. Cangrelor is also an active compound administered intravenously, and its metabolization is 
independent from the hepatic CYP enzymes. Bold letters indicate major enzymes of the metabolic steps. 
hCE1: human carboxylesterase 1 (primarily synthetized by the liver), hCE2: human carboxylesterase 2 
(primarily synthetized by the intestine). CYP: cytochrome p450 enzymes.  
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Table 1. Pharmacological profiles of currently approved P2Y12 inhibitors.  
 
ticlopidine clopidogrel prasugrel ticagrelor cangrelor 
Group based on 
chemical 
structure 
1st generation 
thienopyridine 
2nd generation 
thienopyridine 
3rd generation 
thienopyridine 
cyclo-
pentyltriazolo-
pyrimidine 
ATP-analogue 
Way of 
administration 
Oral (bid) Oral Oral Oral (bid) Intravenous 
Receptor 
inhibition 
Irreversible Irreversible Irreversible Reversible Reversible 
Onset of action 6 h 2-8 h 30 min-4 h 30 min-2 h Seconds 
Offset of action 7-10 d 7-10 d 7-10 d 3-5 d cca. 60 min 
Main enzymes of 
CYP 
metabolization 
CYP2C19,  
CYP2B6,  
CYP3A4 (?) 
CYP1A2, 
CYP2B6,  
CYP2C19, 
CYP3A4, 
CYP3A5 
CYP2B6, 
CYP3A4 
CYP3A4, 
CYP3A5 
- 
Reported 
significant drug-
drug interactions 
yes yes no yes no 
 
1.2.1.3. GPIIb/IIIa receptor inhibitors  
The platelet specific GPIIb/IIIa receptor is the final common pathway of platelet 
aggregation, being the receptor for fibrinogen with the highest affinity and binding also 
fibronectin, vitronectin and vWF [46]. Blocking this final step by intravenously 
administered GPIIb/IIIa inhibitors results in very efficient platelet inhibition, but also in 
increased risk of bleeding. These antiplatelets have different pharmacological features. 
Abciximab is a monoclonal antibody fragment and causes impaired platelet function for 
several days [47]. In contrast, eptifibatide (a low-molecular weight heptapeptide) and 
tirofiban (a non-peptide tyrosine derivative) shows more rapid dissociation from the 
GPIIb/IIIa receptor and restoration of normal hemostatic function after their cessation is 
expected after 3-4 hours [47]. In current clinical practice, the use of GPIIb/IIIa 
inhibitors is limited to bail-out situations -in patients with low bleeding and high 
thrombotic risk- for a short period of time during and immediately before and after PCI 
in patients with ACS [48]. 
1.2.1.4. PDE inhibitors  
Phosphodiesterase enzyme breaks down the intracellular cAMP resulting in enhanced 
platelet activity by increasing the intracellular Ca2+ level. By inhibiting PDE, cilostazol 
and dipyridamole effectively lowers platelet reactivity. Dipyridamole is primarily 
approved for the secondary prevention of transient ischemic attack. Cilostazol is also a 
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direct arterial vasodilator mainly used in patients with PAD [49]. It was also tested in 
former studies, whether adding these agents to DAPT could overcome high on-
treatment platelet reactivity in PCI treated patients, though due to controversial results, 
they did not bring any break-through in antithrombotic treatment [50-52]. 
1.2.1.5. Antiplatelets under development  
There are further promising targets for platelet inhibition. Thrombin, the most potent 
agonist activates platelets through the PAR receptor family. Human platelets express 
PAR1 and PAR4 receptors. By inhibiting the PAR1 receptor, only the effects of thrombin 
on platelets are prevented without impairing effects on coagulation or other functions. 
The recently approved PAR1 inhibitor in clinical use is vorapaxar [53]. Other 
antiplatelet agents being under clinical investigation/development include compounds 
targeting the P2Y1 receptor, the 5-HT receptors, the prostaglandin receptors (IP, EP1-4), 
the GPVI main collagen receptor, the GPIb-VWF axis, the thromboxane receptors and 
the phosphatidylinositol-3-kinase intracellular pathway (see Figure 3, indicated with 
orange color) [54,55].  
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Figure 3. The antiplatelet agents’ sites of action. Currently approved drugs are indicated with black 
bold text in frame, agents under development are signed with orange color. Black arrows denote 
stimulation, red lines depict inhibition. Thromboxane protein receptor inhibitors have not been proven to 
be superior to aspirin up to date [56-58]. The P2Y1 inhibitors MRS2179 and MRS2500 and the PI3K 
inhibitor TGX-221 are only for research use currently [59,60]. The safety trial of additional use of the 
serotonin antagonist APD-791 beside clopidogrel/aspirin therapy has not yet started patient recruitment 
(NCT02034292). The EP3 prostaglandin receptor antagonist DG-041 has only been investigated in Phase 
I clinical trials [61]. The GPIb antibody 6B4-Fab and the GPVI antagonist kistomin and revacept were 
evaluated only in preclinical studies up to date [62-64]. The evaluation of PAR-1 receptor antagonist 
atopaxar was suspended after phase II clinical trials due to safety concerns [65,66] . For abbreviations see 
legend of Figure 1. 
1.2.2. Antiplatelet strategies and current clinical guidelines in patients with SCAD 
The antiplatelet regimens in SCAD are summarized in Table 2. ASA treatment is 
indicated before elective stenting and a loading dose is recommended if the patient is 
not pre-treated. Clopidogrel loading is not recommended routinely, until coronary 
anatomy is not known. After elective PCI, dual antiplatelet treatment is recommended 
with aspirin and clopidogrel for at least 1 month after BMS deployment and 6-12 
months after DES insertion. General use of GPIIb/IIIa inhibitors and prasugrel or 
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ticagrelor is not recommended in these patients, as they may increase bleeding risk [67]. 
In SCAD lifelong administration of low dose aspirin (75-150 mg daily) is recommended 
in all patients. In case of aspirin intolerance or allergy, clopidogrel may be considered. 
Use of platelet function testing is recommended only in specific, high risk situations 
when it may have potential therapeutic consequences [48,67]. 
Table 2. Recommendations for antiplatelet treatment in patients with SCAD undergoing PCI based on the 
current ESC guidelines [48,67]. 
Recommendations for antiplatelet therapy in SCAD patients Class
1
 Level
2
 
Pretreatment   
Clopidogrel 600 mg loading dose  is recommended in elective PCI patients once coronary anatomy is known and 
decision to proceed with PCI is made (≥2 hours before PCI). 
I A 
Pretreatment with clopidogrel may be considered in patients with high probability for significant CAD. IIb C 
In patients already on a 75 mg clopidogrel, a new loading dose of 600 mg or more may be considered 
once the indication for PCI is confirmed. 
IIb C 
During PCI 
  
ASA is indicated for elective stenting. I B 
ASA loading (oral 150-300 mg, i.v. 80-150 mg) is recommended if not pretreated. I C 
Clopidogrel is recommended for elective stenting (≥600 mg loading, 75 mg maintenance dose). I A 
GPIIb/IIIa inhibitors may be used only for bail-out. IIa C 
After stenting 
  
DAPT is indicated for at least 1 month after BMS implantation. I A 
DAPT is indicated for 6 months after DES implantation. I B 
Shorter DAPT duration (<6 months) may be considered after DES implantation in patients at high bleeding risk.  IIb A 
Longer DAPT duration (>6 months) may be used in patients at high ischemic and low bleeding risk. IIb C 
Life-long single antiplatelet therapy, usually ASA, is recommended. I A 
Use of PF testing 
  
PF testing may be used in specific or high risk situations (e.g. history stent thrombosis; compliance issue; suspicion 
of resistance; high bleeding risk) if results may change the treatment strategy. 
IIb C 
Routine platelet function testing to adjust antiplatelet therapy before or after elective stenting is not recommended. III A 
 
1.2.3. Antiplatelet strategies and current clinical guidelines in ACS 
In patients with STEMI, P2Y12 inhibitor therapy should be initiated orally as early as 
possible before angiography, usually at first medical contact (Table 3). Upstream use of 
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GPIIb/IIIa antagonists may also be considered in high risk patients undergoing transfer 
that delays PCI. ASA loading should be performed in all cases. According to the current 
guidelines [39,48], the first choice of P2Y12 inhibitors are prasugrel or ticagrelor  
because of their more rapid onset of action and greater platelet inhibitory potency 
compared to clopidogrel [41,42]. Clopidogrel should be used only in lack of availability 
of the newer agents or in case of contraindications.  
Table 3. Recommendations for antiplatelet treatment in patients with STEMI undergoing primary PCI 
based on the actual ESC guidelines [39,48]. 
Recommendations for antiplatelet therapy in STEMI patients Class1 Level2 
Pretreatment   
It is recommended to give P2Y12 inhibitors at the time of first medical contact. I B 
Upstream use of a GPIIb/IIIa inhibitor (vs. in-lab use) may be considered in high-risk patients undergoing transfer 
for primary PCI. 
IIb B 
During  and after PCI 
  
ASA is recommended for all patients without contraindications at an initial oral loading dose of 150–300 mg (or 
80–150 mg i.v.) and at a maintenance dose of 75–100 mg daily long-term regardless of treatment strategy. 
I A 
A P2Y12 inhibitor is recommended in addition to ASA and maintained over 12 months unless there are 
contraindications such as excessive risk of bleeding. Options are: 
I A 
• Prasugrel (60 mg loading dose, 10 mg daily dose) if no contraindication I B 
• Ticagrelor (180 mg loading dose, 90 mg twice daily) if no contraindication I B 
• Clopidogrel (600 mg loading dose, 75 mg daily dose), only when prasugrel or ticagrelor are not 
available or are contraindicated 
I B 
GPIIb/IIIa inhibitors should be considered for bail-out or evidence of no-reflow or a thrombotic complication. IIa C 
 
In NSTE-ACS, recommendations for antiplatelet treatment are similar, with the 
exception of upstream use of GPIIb/IIIa inhibitors and pre-treatment of prasugrel, which 
regimens are not recommended in patients in whom coronary artery anatomy is not 
known (Table 4). 
After any type of acute coronary syndrome treated with PCI, fibrinolysis or 
medically, long term dual antiplatelet treatment is recommended. Regarding aspirin, 
low dose maintenance therapy should be used indefinitely due to its well established 
benefits in secondary prevention. In case of aspirin intolerance or allergy, clopidogrel 
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might be used instead. Duration of parallel P2Y12 therapy is usually recommended to 
last up to 12 month.  
Table 4. Recommendations for antiplatelet treatment in patients with NSTE-ACS undergoing PCI 
according to current ESC guidelines [40,48]. 
Recommendations for antiplatelet therapy in NSTE-ACS patients Class
1
 Level
2
 
Pretreatment   
Pre-treatment with prasugrel in patients in whom coronary anatomy is not known, is not recommended. III B 
Pre-treatment with GPIIb/IIIa antagonists in patients in whom coronary anatomy is not known, is not 
recommended. 
III A 
During  and after PCI 
  
ASA is recommended for all patients without contraindications at an initial oral loading dose of 150–300 mg 
(or 80–150 mg i.v.), and at a maintenance dose of 75–100 mg daily long-term regardless of treatment strategy. 
I A 
A P2Y12 inhibitor is recommended in addition to ASA, and maintained over 12 months unless there are 
contraindications such as excessive risk of bleeding. Options are: 
I A 
• Prasugrel (60 mg loading dose, 10 mg daily dose) in patients in whom coronary anatomy is known and 
who are proceeding to PCI if no contraindication I B 
• Ticagrelor (180 mg loading dose, 90 mg twice daily) for patients at moderate-to-high risk of ischemic 
events, regardless of initial treatment strategy including those pre-treated with clopidogrel if no 
contraindication 
I B 
• Clopidogrel (600 mg loading dose, 75 mg daily dose), only when prasugrel or ticagrelor are not 
available or are contraindicated I B 
GPIIb/IIIa antagonists should be considered for bail-out situation or thrombotic complications. IIa C 
 
1.3. Laboratory monitoring of platelet function in current cardiology practice 
There are several laboratory methods to measure platelet function, most of which were 
primarily developed to screen and detect hereditary and acquired platelet/primary 
hemostasis disorders. Since the use of dual antiplatelet therapy results in acquired 
platelet dysfunction, most of these tests were challenged in monitoring the efficacy of 
antiplatelet therapy, though with various success. The more functional aggregometry 
tests give more information about the overall platelet reactivity and are less specific for 
the inhibitory effect of a given drug. In contrast, more specific tests assessing the 
inhibitory effect of a drug at the subcellular level might be less informative about the 
overall function of the activation-aggregation cascade. In the next session I will provide 
a non-exhaustive overview of the most often used platelet function tests in cardiology 
practice. The most widely applied tests are summarized in Table 7 (see below). 
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1.3.1. Aggregometry methods 
Platelet activation finally results in platelet aggregation, which can be detected by 
several functional aggregometry methods. These tests measure the ability of different 
platelet agonists to induce platelet activation and aggregation in vitro. 
1.3.1.1. Light transmission aggregometry (Born aggregometry) 
The gold standard of aggregometry methods is light transmission aggregometry, also 
referred as the Born-method, introduced by Gustavo Born more than 50 years ago 
[68,69]. The method detects the decrease in optical density of the platelet rich plasma 
which occurs when the platelets in it aggregate due to activation with an agonist. 
Change in optical density is depicted as a function of time. PRP is prepared by 
centrifugation and is basically free of other blood cellular elements. The standard used 
in the measurement is the platelet poor plasma of the same subject (PPP, prepared by 
further centrifugation), representing the minimum of optical density (or the maximum of 
light transmittance). 
 In spite of the wide-spread use of LTA for detecting platelet function, it is often 
criticized because of comparability difficulties of the obtained results. The method is 
fairly non-standardized, concerning pre-analytical processes (blood sampling, 
preparation of PRP, circumstances and time of sample storage until the measurement), 
agonists of different sources and concentrations, as well as the settings of the recorder 
[70] or the measurement parameter to be evaluated (e.g. maximal aggregation, final 
aggregation and disaggregation) [71,72]. The most widely used agonists are collagen, 
epinephrine, ADP, TRAP, and arachidonic acid. 
 Most initial data about the association of high on-treatment platelet reactivity 
and recurrent ischemic events in CAD patients after PCI raised from studies using the 
LTA method [73-75]. Moreover, in a comparative platelet function study, LTA was able 
to predict recurrent ischemic events during 1 year follow-up [76]. However, because of 
the non-standardized, labor-intensive procedure of the LTA method it is not advised for 
monitoring the efficacy of dual antiplatelet therapy in every-day clinical practice 
according to the latest consensus document [77]. 
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1.3.1.2. VerifyNow method 
 The VerifyNow is a semi-automated, standardized point-of-care method to measure 
platelet aggregation in whole blood. Activated platelets aggregate to fibrinogen-coated 
microbeads, decreasing the optical density of the sample. The P2Y12 assay includes 
ADP agonist along with prostaglandin E1, which increases the sensitivity of the test and 
can be successfully used to assess P2Y12 therapy [78-80]. The VerifyNow Aspirin test 
uses arachidonic-acid agonist and assesses the thromboxane A2 mediated activation 
pathway. VerifyNow has been widely and successfully used to measure the efficacy of 
DAPT and its association with clinical outcome and the benefit of tailored antiplatelet 
therapy in patients undergoing PCI [81-84]. 
1.3.1.3. Multiple electrode aggregometry (Multiplate)  
Multiple electrode aggregometry or impedance aggregometry is based on detection of 
impedance change caused by the adherence of platelets after activation with an agonist 
to multiple electrode-pairs immersed in the whole blood sample. The change of 
impedance is depicted as a function of time, and the area under the curve value given in 
units (U) indicates the measure of platelet reactivity [85]. Multiplate is a semi-
automated, standardized point-of-care device, with the following available assays: ADP 
test and high sensitive ADP test (with use of PGE1 to eliminate false-positive results) to 
monitor P2Y12 inhibitor therapy, ASPI test (arachidonic-acid agonist) to monitor ASA 
therapy, and other non-specific assays such as TRAP test (TRAP-6 agonist), and COL 
test (collagen agonist), RISTO test (ristocetin agonist) to examine the vWF and GpIb 
dependent aggregation (e.g. to detect von Willebrand’s disease). The Multiplate ADP 
test was widely used in clinical studies assessing the efficacy of dual antiplatelet therapy 
[86] and it was found to be capable to predict ischemic [87] or bleeding events [88,89] 
in PCI treated patients. 
1.3.1.4. Plateletworks 
 In this standardized, point-of-care method, aggregation testing in whole blood is based 
on the comparison of a platelet count performed before and after provoking platelet 
activation, using different agonists. Though, the method is not widely used and/or 
investigated, it was successfully tested in a comparative platelet function study, where 
its results were associated with occurrence of ischemic events during 12 months follow-
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up [76]. Also, it was found to be capable to identify patients at higher risk of myocardial 
infarction and rehospitalization within 3 months after coronary angiography [90]. 
1.3.1.5. Platelet function analyzer 100 (PFA-100)  
This automated point-of-care method was developed to screen primary hemostatic 
disorders (e.g. von Willebrand’s disease). In this device, whole blood sample flows at 
high shear rates through an aperture in a membrane which is coated with distinct 
agonists and leads to rapid occlusion of the aperture, referred as the closure time. The 
COX inhibitors usually prolong the closure time of the collagen/epinephrine cartridge, 
therefore the method has often been used to measure functional aspirin resistance [91]. 
However, clopidogrel’s efficacy [92] and its association with clinical outcomes cannot 
be assessed with this method [76]. 
1.3.1.6. Impact-R (cone and plate(let) analyzer - CAP)  
By this method the anticoagulated whole blood sample is added to a polystyrene well. 
Platelet activation is induced by application of shear stress and aggregates are visualized 
and quantified by staining. The results are expressed as percentage of well surface 
covered by aggregates (SC) as an index of adhesion and average aggregate size (AS) as 
an index of aggregation [93]. Agonist-induced aggregation was suggested to be capable 
to monitor antiplatelet therapy [94]. However, in a comparative platelet function testing 
study, Impact-R failed to discriminate between patients with and without major 
cardiovascular events at 1 year follow-up after PCI [76]. 
1.3.2. Other methods to detect platelet activation 
There are several other tests to measure platelet activation by detecting appearance of 
activation markers on the platelets’ surface or soluble activation markers in the plasma 
(representing cleaved and shed surface glycoprotein fragments), and structural changes 
of membrane or intracellular regulatory proteins. 
1.3.2.1. Flow cytometry  
Flow cytometry can measure several aspects of platelet activation [95]. After 
stimulation of platelets by an agonist, different markers of activation can be measured 
with the help of fluorescent antibodies (e.g. P-selectin exposure, activated GPIIb/IIIa 
expression, binding of fibrinogen). In a comparative study, ADP induced aggregometry 
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(VerifyNow, LTA and MEA) and flow cytometry results correlated significantly in PCI 
treated patients on DAPT [96]. In contrast, after AA induction, correlations were only 
partially observed. Also, association of platelet activation detected by flow cytometry 
with clinical outcome is fairly unknown yet. Furthermore, due to expense of the unit and 
need for labor-intensive sample preparation, flow cytometry is not practical for 
monitoring DAPT at point-of care.  
1.3.2.2. VASP test  
Over a decade ago, an important new technique has been introduced by using fixed and 
permeabilized platelets and specific labeling of the intra-cellular regulatory protein 
vasodilator-stimulated phosphoprotein [97]. It is phosphorylated through the cAMP 
biochemical cascade, indicating P2Y12 receptor inhibition and its dephosphorylation 
indicates P2Y12 receptor activity [98], thus the VASP assay can be used to monitor 
P2Y12 inhibitor therapy. Results of this assay correlate well with those of distinct 
platelet aggregometry methods [99-101]. Though VASP assay was described to be 
capable to predict adverse ischemic events after PCI [102], its discriminative capacity 
was lower than that of the aggregometry methods [103]. 
1.3.2.3. Measurement of soluble activation markers  
An alternative way to assess platelet function is to find a reliable plasma marker that 
reflects platelet activation and is a specific marker of the platelet, is not affected by 
artefacts of sample collection, and is measureable by a reproducible and simple 
laboratory technique. Possible candidate molecules can be substances that are released 
from the platelet’s granules, molecules that are expressed on and shed from the 
platelet’s surface, and secreted metabolic molecules [104]. In spite of high former 
interest, none of these markers could fulfill the above mentioned criteria, thus their 
clinical utility is controversial at this point [105]. 
1.3.2.4. Thromboelastography (TEG, ROTEM)  
This is a viscoelastic hemostatic assay, which analyzes clot formation (time to initial 
fibrin generation), clot elasticity development (clot strength) and the process of 
fibrinolysis. Elasticity of the clot is influenced by several factors, such as the contractile 
force of platelets during clot retraction (which is the major determinant), platelet and 
fibrinogen concentration, hematocrit, FXIII and the thrombin generation during 
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coagulation [106]. TEG is most widely used in surgery and anesthesiology and was less 
extensively investigated in monitoring DAPT therapy in cardiology patients, however 
some data suggested that clot strength and rapid fibrin formation beside DAPT were 
risk factors of recurrent ischemic events in patients after PCI [73].  
1.4. Definition and clinical significance of high on-treatment platelet reactivity 
1.4.1. Clinical and laboratory approach to the efficacy of antiplatelet therapy 
Since the introduction of percutaneous coronary intervention in the therapeutic toolbar 
of coronary artery disease, many procedural and pharmaceutical improvements have 
been carried out. The spread of drug eluting stents successfully decreased the 
occurrence of restenosis, though they brought along a new complication in the form of 
late and very late stent thrombosis. Regarding antiplatelet therapy, which is a sine qua 
non in the success of percutaneous coronary intervention and intracoronary stenting, it 
has been proven, that adding clopidogrel to aspirin was more effective in preventing 
recurrent ischemic events in the long term compared to aspirin monotherapy [32,33]. 
Furthermore, DAPT was shown to decrease the long term rate of both ischemic and 
bleeding events compared to aspirin combined with an anticoagulant (heparin or 
coumarin) [107,108] or an oral GPIIb/IIIa inhibitor [109]. However, in spite of the 
application of dual antiplatelet therapy after PCI, ischemic events such as stent 
thrombosis and myocardial infarction still continued to occur, therefore the terms 
“treatment failure” and “aspirin and clopidogrel resistance” emerged. Treatment failure 
refers to the state, when an adverse clinical event/condition recurs despite the 
administration of a drug to avoid it. In the literature, “aspirin and clopidogrel resistance” 
referred to the condition, when the lack of aspirin/clopidogrel’s effect was justified by a 
laboratory platelet function test. However, in pharmacology, drug resistance means 
inability of a drug to hit its therapeutic target (e.g. receptor, enzyme or regulatory 
protein) either from a pharmacokinetic (e.g. impaired intestinal absorption leading to 
suboptimal concentration of the drug at the effect site) or from a pharmacodynamic 
(meaning that the target protein itself is impaired/altered) cause. Usually, platelet 
function tests are not capable to assess these details of antiplatelet mechanism of action. 
Thus, laboratory proven aspirin and clopidogrel “resistance” was replaced by the term 
“high on-treatment platelet reactivity” (HPR) or “residual platelet reactivity/activity” 
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(RPR/RPA). With respect to the applied antiplatelet therapy and platelet function test 
we may differentiate “high on-clopidogrel and high on-aspirin platelet reactivity” 
(HCPR and HAPR) or “dual high on-treatment platelet reactivity”.  
 
1.4.2. Clinical significance of measuring aspirin-effect and high on-aspirin platelet 
reactivity (HAPR) 
Measuring the efficacy of aspirin treatment proved to be more complicated and less 
reliable from the methodological aspect, than that of the P2Y12 inhibitors [110,111]. 
Methods to monitor aspirin therapy include measuring of serum TXB2 (the stable 
metabolite of TXA2) concentrations or detecting the urine TXB2 or 11-dehydro-
thromboxane-B2 level [111]. However, these measurements are complicated and these 
metabolites might be generated through COX-1 independent pathways as well, thus they 
rather reflect an overall inflammatory state, than the measure of aspirin-effect. 
Therefore, the inhibitory effect of aspirin most widely is measured indirectly in platelet 
function tests using arachidonic-acid as an agonist (via the induction of TXA2 
generation and consequent platelet activation) [112]. Many non-specific antagonists 
(ADP, collagen, and epinephrine) are also rely on TXA2 generation as an amplification 
loop, therefore were used in the laboratory determination of aspirin response. However 
these tests overestimate the prevalence of true aspirin non-response [110,113]. 
 To date, the predictive value of measuring aspirin-effect in association with 
clinical outcome is controversial. In early studies, the “aspirin-resistant” phenotype was 
associated with higher risk of ischemic events, however in these studies patients were 
on aspirin monotherapy usually and non-aspirin specific platelet function tests were 
used [114-117]. Therefore, these tests rather identified patients with a “hyper-reactive 
platelet phenotype”, than measured aspirin’s platelet inhibitory effect via the COX1 
inhibition.  
Recently, the largest clinical trial investigating high on-treatment platelet 
reactivity on aspirin and clopidogrel so far found no association between on-aspirin 
treatment platelet reactivity assessed by VerifyNow Aspirin test and all cause death, 
stent thrombosis or myocardial infarction, though HAPR was inversely related to 
bleeding [81]. Similarly, another large scale study failed to link high residual platelet 
reactivity on aspirin measured by PFA-100 to clinical outcome [118]. On the other 
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hand, recent data from a large scale, one center registry suggested, that patients with 
HAPR identified by the Multiplate ASPI test (using AA induction) showed a 
significantly higher risk of death or ST at 1 year and HAPR was an independent 
predictor of the combined primary outcome [119]. Similarly, dual high on-treatment 
platelet reactivity to aspirin and clopidogrel was associated with a higher risk for 
atherothrombotic events and identifies patients at highest thrombotic risk [120,121]. 
Whether or not HAPR is associated with clinical outcome, the benefit of aspirin 
dose adjustment based on laboratory efficacy testing is questionable anyway. Several 
clinical data justified that overcoming HAPR by increasing aspirin dose only increased 
the risk of bleeding, without further improving ischemic outcomes [122,123]. Since 
such a therapeutic modification is not recommended, reasonableness of assessing HAPR 
currently remains debated. 
In summary, in contrast to high on-clopidogrel platelet reactivity, the term “high 
on-aspirin treatment platelet reactivity” and “aspirin resistance” are less clearly defined 
and have a widely variable prevalence in the literature [124], and though some data 
suggest, that HAPR along with HCPR might be helpful in thrombosis risk stratification, 
its clinical significance remains controversial. Consequently, the following part of this 
thesis will focus on high platelet reactivity on P2Y12 inhibitor therapy. 
 
1.4.3. High on-clopidogrel platelet reactivity (HCPR) and high platelet reactivity on 
P2Y12 inhibitor therapy (HPR) 
In the past decade, extensive research has been focused on the association of laboratory 
certified HCPR and recurrent ischemic events resulting in growing evidence, that HCPR 
and HPR are independent risk factors of thrombotic events after PCI [77,81,125]. The 
largest studies (N>300) investigating the existence and strength of an association 
between on-treatment platelet reactivity and clinical outcome are summarized in Table 
5. 
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Table 5. Major studies linking on-treatment platelet reactivity with clinical outcome 
First 
author 
(year), 
Study 
name 
No. of patients 
and 
presenting 
clinical 
syndrome 
Platelet function 
test(s)/applied 
P2Y
12
 inhibitor 
Cut-off  
for HPR 
Cut-off 
for LPR  
OR [95% CI] for  
ischemic event(s)* 
OR [95% CI] for 
bleeding event(s)* 
Follow-up 
time 
Sibbing 
(2010) 
[88] 
308 NSTEMI 
/STEMI 
2245 
UAP/SCAD 
Multiplate ADP/ 
clopidogrel 
>46 U <19 U 
6.44 [2.38–17.38] for 
def ST** 
2.6 [1.3–5.2] 
for in hospital TIMI 
major bleeding 
30 days 
Geisler 
(2010) 
[126] 
514 SCAD 
505 ACS 
LTA 20 µM ADP/ 
clopidogrel 
Upper tertile 
border for 
FA >42.5% 
NR 
HR 1.05 [1.01–1.08] 
for early (<30 days) 
stent thrombosis 
2.21 [1.31–3.73] for 
combined CV end 
point 
2.31 [1.1–4.84] for all 3 
month ST 
NR 3 months 
Breet 
(2010), 
POPular 
[76] 
1069 
elective PCI 
LTA 5 µM ADP 
LTA 20 µM ADP 
VerifyNow P2Y
12
 
Plateletworks/ 
clopidogrel 
MA ≥42.9% 
MA≥ 64.5% 
≥ 236 PRU 
≥ 80.5% 
 
NR 
2.09 [1.34-3.25] 
2.05 [1.32-3.19] 
2.53 [1.63-3.91] 
2.22 [1.25-3.93] 
for combined CV end 
point 
No association was 
found between TIMI 
major or minor 
bleeding and any of 
the PF tests. 
1 year 
Park 
(2011) 
[127] 
1586 SCAD 
1264 ACS 
VerifyNow P2Y
12
/ 
Clopidogrel 
>235 PRU 
and/or % 
inhibition <15 
<235 
PRU 
HR 1.33 [0.88–2.01] 
for combined CV end 
point 
1.45 [0.27–7.92] for 
def/prob ST 
HR 0.78 [0.35–1.69] 
for TIMI major 
bleeding 
2 years 
Bonello 
(2012) 
[128] 
128 STEMI 
100 NSTEMI 
73 UAP 
VASP/ 
prasugrel 
≥53.5 % PRI 
<16 % 
PRI 
1.44 [1.2–1.72] per 
10% increase for 
def/prob ST 
0.75 [0.59–0.96] per 
10 % increase for 
TIMI major and 
minor bleeding 
1 year 
Siller-
Matula 
(2012), 
PEGASUS-
PCI [129] 
274 elective 
PCI 
67 NSTE-ACS 
73 STEMI 
Multiplate 
ADP+PGE
1
/ 
clopidogrel 
≥48 U NR 
36.9 [4.3–319] for 
def/prob ST 
No predictive ability 
was found for TIMI 
major bleeding. 
1 year 
Cuisset 
(2013), 
POBA 
[130] 
1542 ACS 
VASP/ 
25% prasugrel 
75% clopidogrel 
NR 
≤10 % 
PRI 
NR 
4.7 [2.7-8.3] for 
BARC bleeding 
6 months 
Stone 
(2013), 
ADAPT-
DES [81] 
4147 SCAD 
2373 UAP 
1250 NSTEMI 
813 STEMI 
VerifyNow P2Y
12
/ 
Clopidogrel 
>208 PRU 
<95 
PRU 
HR 2.54 [1.55–4.16] 
for def/prob ST, 
HR 1.42 [1.09–1.86] 
for  MI 
HR 1.52 [1.17-1.97] 
for clinically relevant 
bleeding 
1 year 
ACS: acute coronary syndrome; ADP: adenosine-diphosphate; BARC: Bleeding Academic Research 
Consortium; CI: confidence interval; def: definite; FA: final aggregation; HPR: high on-treatment platelet 
reactivity; HR: hazard ratio; LPR: low platelet reactivity; LTA: light transmission aggregometry; NR: not 
reported; NSTEMI: non-ST elevation myocardial infarction; OR: odds ratio; PRI: platelet reactivity 
index; prob: probable; SCAD: stable coronary artery disease; STEMI: ST elevation myocardial infarction; 
TIMI: thrombolysis in myocardial infarction; UAP: unstable angina pectoris; VASP: vasodilator-
stimulated phosphoprotein.*Odds ratios are given unless otherwise indicated. **All ST are defined 
according to Academic Research Consortium criteria. 
Recognition of an association between HPR (mostly on clopidogrel) and clinical 
outcome as well as wide inter-individual variability of platelet inhibition and relatively 
high prevalence of HCPR raised doubt in one-size-fits all dosing method and led to the 
development of more potent P2Y12 receptor inhibitors. However, the price to pay for 
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more expressed platelet inhibition is an increased bleeding risk in unselected patient 
populations [41,42]. Consequently, current recommendations exclude patients with 
stable coronary artery disease and ACS patients at high bleeding risk from the benefit of 
these novel P2Y12 inhibitors [48,131,132]. These patients remain subjects of clopidogrel 
treatment. Notably, the prevalence of high on-treatment platelet reactivity (HPR) only 
diminished but not vanished with the use of novel antiplatelets [133,134].  
On the other hand, recently published data from the ADAPT-DES study 
highlighted further interesting aspects of platelet function testing, verifying that 
overcoming high on-treatment platelet reactivity at any price might profoundly increase 
bleeding risk and through that may counter-balance the favorable effects of intense 
platelet inhibition. The authors discussed it as a potential explanation of the lack of 
association between HPR and mortality [81]. However, association of low platelet 
reactivity on dual antiplatelet therapy with higher bleeding risk [88] and the concept of a 
“therapeutic window” of P2Y12 inhibitor treatment was already introduced in earlier 
studies [77,89]. The fact that prognostic significance of bleeding consequences is 
equally important with that of ischemic events—particularly with the spreading use of 
more potent P2Y12 inhibitors [77,81]— further expands the space for platelet function 
testing.  
1.4.4. Poor response to antiplatelet agents - determining factors of HPR 
Factors associated with high on-clopidogrel platelet reactivity have already been 
investigated by a large number of studies [38] (Table 6). Although certain genetic 
polymorphisms (CYP2C19 loss of function, CYP3A4 and CYP3A5, and ABCB1 gene 
polymorphisms), drug-drug interactions (e.g. CCBs and PPIs) and accompanying 
clinical risk factors such as higher body mass index (BMI), reduced LVF, diabetes 
mellitus, chronic kidney disease, female gender and smoking have already been linked 
to HPR measured by various platelet function tests, there is a lot of discrepancy among 
study results. This discrepancy might derive from the use of distinct platelet function 
tests assessing different aspects of platelet activation/aggregation and variable cut-off 
values as well as from inclusion of platelet reactivity as categorical or continuous 
parameter. Moreover, there is a gap of knowledge regarding the response variability to 
newer antiplatelet agents. 
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Table 6. Response variability to P2Y12 therapy 
Determinants of HPR References 
Clinical factors  
Age [135-137] 
Gender [137-139] 
BMI [103,136,140,141] 
ACS [142,143] 
Renal failure [137,142,144,145] 
Reduced LVF [142,146] 
Smoking [139,147,148] 
Inflammation [149-151] 
Underdosing [152,153] 
Compliance [154] 
Genetic factors  
CYP2C19*2 loss of function [155-157] 
CYP3A4, A5 gene variants [158-160] 
ABCB1 gene variants [161] 
Drug-drug interactions  
PPI (mostly omeprazole) [162-164] 
CCB [135,165,166] 
 
1.4.5. Tailored antiplatelet therapy  
Due to extensive research, several methods for platelet function testing underwent 
clinical validation beside the gold standard optical aggregometry and clinically 
determined cut-off values have been established [76,77,87]. Nevertheless, platelet 
function testing has a fairly variable, but generally low predictive value depending on 
the applied platelet function test, investigated clinical end point, follow-up time and 
clinical presentation of coronary artery disease (CAD) [77,125]. The most recent 
consensus document advices only a few platelet testing method for assessing platelet 
reactivity in cardiology practice [77]. The most widely used and investigated platelet 
function tests are summarized in Table 7.  
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Table 7. The most widely used platelet function tests to measure the efficacy of DAPT. 
 
Multiplate 
6.4 µM ADP 
VerifyNow P2Y12 
20 µM ADP + PGE1 
VASP 
20 µM ADP + PGE1 
LTA*  
variable ADP cc-s 
Point-of-care/ 
standardization 
++/yes +++/yes -/yes -/no 
P2Y
12
 receptor 
specificity 
+ ++ +++ + 
Measurement time < 10 min < 10 min 2-3 h < 10 min 
Cut-off for HPR > 46 U > 208 PRU > 53% PRI 
a, 5 µM ADP induced 
MA > 42.9% 
b, 20 µM ADP induced 
MA > 64.5% 
Name of study or first 
author, derivative 
patient cohort, 
N (%ACS) 
Sibbing [88], 
general PCI, 2533 
(12.16% MI) 
ADAPT-DES [81], 
general PCI, 
8582 (51.7) 
Frere [167], 
195 (100% NSTE-ACS) 
POPular [76], 
elective PCI (0) 
Predictive ability 
for  stent thrombosis, 
OR [95% CI]** 
6.44 [2.38-17.38] HR 2.54 [1.55–4.16] 
PPV 12% 
NPV 99% 
a,2.09 [1.34-3.25]*** 
b, 3.85 [1.18-12.58] 
Cut-off  for LPR < 19 U 
< 95 PRU (upper 
border of the 1st 
quintile) 
< 10% PRI 
10 µM ADP induced MA< 
40% (upper border of the 
1st quartile) 
Name of study or first 
author, derivative 
patient cohort, 
N (%ACS) 
Sibbing [88], 
general PCI, 
2533 (12.16%MI) 
Kirtane [168], 
general  PCI 
8582 (51.7) 
POBA [130], 
1542 (100% NSTE-
ACS) 
Cuisset [169], 
597 (100) 
Predictive ability 
for bleeding, 
OR [95% CI] 
2.6 [1.3–5.2] 1.48 [1.21–1.81] 4.7 [2.7-8.3] 
6.6% vs. 1.4 % 
1st quartile vs. the others 
ADP: adenosine-diphosphate, HPR: high on-treatment platelet reactivity, HR: hazard ratio, MA: maximal 
aggregation, NPV: negative predictive value, NSTE-ACS: non-ST elevation acute coronary syndrome, 
OR: odds ratio, PCI: percutaneous coronary intervention, PPV: positive predictive value, PRI: platelet 
reactivity index, PRU: platelet reactivity unit. *The latest consensus paper does not recommend the use of 
LTA due to its non-standardized features. .**Odds ratios are given unless otherwise indicated. *** OR is 
given to a combined CV end point. 
Parallel to the assessment of distinct platelet function tests, several randomized 
controlled trials have been conducted to investigate the benefit of tailored antiplatelet 
therapy based on platelet function testing. These RCTs and the main prospective cohort 
studies with the same object are summarized in Table 8. The first RCT investigating this 
question was the GRAVITAS trial closing with neutral results, suggesting that doubling 
the clopidogrel dose in patients with HPR on standard 75 mg clopidogrel does not 
improve clinical outcome [84]. The TRIGGER-PCI trial, which investigated the effect 
of prasugrel therapy introduction in HPR patients on 75 mg clopidogrel in comparison 
to continuation of conventional therapy was ceased on half-way of the planned study 
period due to unexpectedly low event rates [83]. In the TRILOGY-ACS platelet 
function substudy, where medically treated NSTE-ACS patients were recruited, 
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randomization to 10 mg prasugrel or conventional clopidogrel therapy did not lead to 
any clinical benefit during 30 month follow-up. However, platelet function in the 
prasugrel arm was significantly decreased compared to the clopidogrel arm during the 
whole study period. This result suggests that maximizing platelet inhibition is not so 
favorable and has less significance in patients without revascularization [170]. 
Table 8. Major studies investigating the clinical benefit of tailored antiplatelet therapy. 
Study name 
and design 
(year) 
Patient number 
(ACS/STEMI %) 
Platelet function 
test (cut-off, HPR 
rate) 
Therapeutic 
modification if 
HPR 
Comparison Primary end 
point 
OR/HR [95%CI] 
for primary end 
point and for ST 
GRAVITAS 
Randomized 
controlled trial 
(2010) [84] 
2214 
(40/0.4) 
VerifyNow P2Y
12
 
(>230 PRU, 41%) 
High dose 
clopidogrel 
(50%) 
75 vs 150 
mg 
clopidogrel 
CV death, MI 
or ST at 6 
month 
HR 1.01 [0.58-1.76] 
HR 0.63 [0.21-1.93]** 
TRIGGER-PCI 
Randomized 
controlled trial 
(2012) [83] 
423 
(0/0) 
VerifyNow P2Y
12
 
(>208 PRU, 100%) 
75 mg 
clopidogrel 
(50%) 
10 mg prasugrel 
(50%) 
75 mg 
clopidogrel 
vs 
10 mg 
prasugrel 
CV death or 
MI at 6 
month 
NE 
NE** 
TRILOGY-
ACS 
Randomized 
controlled trial 
(2012) [170] 
2564 
(100/0) 
VerifyNow P2Y
12
 * 
(>208 PRU, 46%) 
(>230 PRU, 39%) 
75 mg 
clopidogrel 
(50%) 
10 mg prasugrel 
(50%) 
75 mg 
clopidogrel 
vs 10 mg 
prasugrel 
CV death, MI 
or stroke at 
30 month 
HR 1.43 [1.07-1.89] 
NR 
 
ARCTIC 
Randomized 
controlled trial 
(2013) [82] 
2440 
(27/0) 
VerifyNow P2Y12 
(34.5%) 
VerifyNow Aspirin 
(7.6%) 
High dose 
clopidogrel 
(80%) 
Prasugrel (12%) 
High dose ASA 
(85%) 
Guided vs 
conventional 
arm wo PF 
testing 
All-cause 
death, MI, 
urgent 
revasc., 
stroke, ST at 
1 year 
HR 1.13 [0.98-1.29] 
HR 1.54 [0.56-3.18]*** 
RECLOSE-2-
ACS 
Prospective 
registry 
(2011) [171] 
1789 
(100/46) 
LTA 10 µM ADP 
(14%) 
High dose  
clopidogrel (NR) 
Ticlopidine (NR) 
Guided HPR 
vs no HPR 
CV death, 
MI, urgent 
revasc., 
stroke at 2 
years 
OR 1.80 [1.21-2.68] 
OR 2.18 [1.19-3.97]*** 
MADONNA 
Prospective 
registry 
(2012) [172] 
798 
(37/12) 
Multiplate ADP 
(26%) 
High dose 
clopidogrel 
(12%) 
Prasugrel (14%) 
Non-guided 
arm wo 
therapy 
modification 
vs guided  
Def/prob ST 
at 30 days 
OR 7.9 [1.08-69.2] 
ISAR-HPR 
Historical 
control cohort 
study  
(2014) [173] 
999 
(50/15) 
Multiplate ADP 
(100%) 
High dose 
clopidogrel 
(15%) 
Prasugrel (20%) 
Guided vs 
conventional 
cohort wo 
therapy 
modification 
All-cause 
death or ST 
at 30 days 
HR 0.71 [0.39-1.30] 
HR 0.31 [0.11-0.87]** 
PÉCS 
REGISTRY 
Prospective 
registry 
(2014) [174] 
741 
(100/48) 
Multiplate ADP 
(29.5%) 
High dose 
clopidogrel 
(58%) 
Prasugrel (42%) 
High dose 
clopidogrel 
vs prasugrel 
group 
All-cause 
death, MI, ST 
or stroke at 1 
year 
OR 2.67 [1.20-5.96] 
OR 1.96 [0.50-7.58]** 
* Randomization before PF testing. ** Definite/probable stent thrombosis *** All stent thromboses. NE: 
not estimated due to insufficient data. NR: not reported. See abbreviations above at Table 5 and 7.  
The largest trial studying tailored antiplatelet therapy up to date was the ARCTIC trial 
[82]. This trial investigated different therapy modification algorithms (including 
repeated clopidogrel loading dose and elevated -150 mg- clopidogrel maintenance dose 
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administration, additional GPIIb/IIIa inhibitor application or in a smaller fraction of 
patients, switch to prasugrel maintenance treatment with the use of an initial prasugrel 
loading dose) based on platelet function testing and compared the clinical outcome of 
these patients with that of a conventionally treated arm on 75 mg clopidogrel, where no 
platelet function testing was applied. In this trial therapy modification did not improve 
the clinical outcome of the patients compared to the conventionally treated arm. 
However, heterogeneous therapy modification algorithms were used according to the 
treating physician and therapy adjustment in the opposite direction (dose reduction or 
switch to a less potent antiplatelet drug) was also performed when too intense platelet 
inhibition was noticed. 
In summary, the results of the above clinical studies do not support the concept 
of tailored antiplatelet therapy based on routine platelet function testing. However, these 
studies were conducted completely (TRIGGER-PCI) or mainly in elective PCI cohorts 
(GRAVITAS 60.2%, ARCTIC 73%) representing rather low-intermediate risk patients 
or in medically treated NSTE-ACS patients. Consequently, there are relatively few data 
on the role of tailored antiplatelet therapy in invasively treated ACS patients with the 
highest thrombotic risk.  
Though routine platelet function testing is not recommended by the current 
guidelines, more recent data suggest that tailored antiplatelet therapy may reduce 
thrombotic and bleeding risk in the ACS patient cohort [174]. Currently, therapeutic 
decisions at the individual level are further aggravated by widened supply of antiplatelet 
agents, different biological drug profiles, considerable efficacy/safety issues and the 
pronounced heterogeneity of cardiovascular patients. Thus, monitoring platelet 
reactivity beside obvious clinical parameters might provide important contributory data 
to identify patients at higher ischemic or bleeding risk in the acute setting of CAD. 
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2. OBJECTIVES 
 
As we reviewed in the introduction section, there is a lack of knowledge regarding the 
clinical benefit of platelet function testing and tailored antiplatelet therapy in acute 
coronary syndrome patients at high thrombotic risk. Therefore, first we aimed to 
investigate the incidence of high on-treatment platelet reactivity, the effect of intensified 
antiplatelet therapy and long term follow-up of platelet function in patients with 
myocardial infarction and stable coronary artery disease. Secondly, we analyzed 
predictors of high on-clopidogrel platelet reactivity measured by a clinically recently 
available point-of-care method in a high thrombotic risk cohort represented by acute 
coronary syndrome patients. Detailed objectives of our studies were the followings: 
 
1. To assess platelet function values and the rate of high on-clopidogrel platelet 
reactivity (HCPR) measured with light transmission aggregometry among patients with 
myocardial infarction (MI) and patients with stable coronary artery disease (SCAD).  
2. To assess the influencing clinical and demographical factors of platelet reactivity 
measured by LTA. 
3. To optimize antiplatelet therapy in patients with HCPR until laboratory certified 
platelet inhibition is achieved in patients with MI and SCAD.  
4. To conduct a long-term follow up of individually tailored antiplatelet therapy with 
repeated platelet function testing and registration of clinical outcome data in patients 
with MI and SCAD.  
5. To identify predictors of HCPR measured with the point-of-care multiple electrode 
aggregometry in the acute coronary syndrome patient cohort with high thrombotic risk. 
6. To develop a HCPR risk prediction model and perform HCPR risk stratification of 
patients with ACS. 
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3. METHODS 
 
To answer the above questions we conducted two prospective studies on separate 
patient cohorts. 
3.1. Monitoring and optimizing antiplatelet therapy in patients with myocardial 
infarction and stable coronary artery disease 
3.1.1. Patient population and study design 
We enrolled 200 patients into our study: 133 patients with myocardial infarction (MI) 
(105 patients with ST elevation myocardial infarction and 28 patients with non-ST 
elevation myocardial infarction) and 67 patients with stable coronary artery disease 
(SCAD). All patients underwent PCI and intracoronary stenting (bare metal stent or 
drug eluting stent implantation).  
A loading dose of 600 mg clopidogrel was given to all patients in the MI group 
and to clopidogrel naive patients in the SCAD group. MI patients were given 75 or 150 
mg clopidogrel maintenance dose based on the physician’s decision. Determining 
factors were age, gender, body weight, and comorbidities of the patients. According to 
our current institutional practice, higher doses of clopidogrel were applied in the first 30 
days after PCI, then standard 75 mg clopidogrel for the whole study period. In the 
SCAD group, clopidogrel maintenance dose was 75 mg daily. All patients were given 
≥100 mg aspirin daily (in 5 cases 300 mg daily dose was applied according to the 
physician’s decision.) 
The exclusion criteria were as follows: history of severe renal or hepatic disease, 
hematological or hemostatic disorders, acute or chronic inflammatory disease, active 
malignancy and active bleeding. The study protocol was approved by the institutional 
ethics review committee, and a written informed consent was obtained from all patients 
before enrolment. 
 
3.1.2. Aggregometry measurements 
Platelet function was measured with LTA (Carat TX4, Budapest, Hungary) 72 hours 
after PCI in the MI group and 24 hours after PCI in the SCAD group. Measurement 
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details are described previously [175] . Briefly, blood was drawn from the cubital vein 
into citrate-anticoagulated tubes (final concentration was 3.2%). Platelet rich plasma 
was separated by centrifugation at 980 rpm for 10 minutes. Platelet poor plasma was 
prepared by further centrifugation at 3000 rpm for 10 minutes. Platelet agonists were 10 
μM epinephrine (EPI), 1 μg/ml collagen (COLL) and 0,5 μg/ml AA to assess overall 
platelet reactivity and 1,25 μM; 5 μM; 10 μM ADP to assess clopidogrel’s effectiveness 
specifically. Measuring time was 7 minutes and maximal aggregation was determined in 
percentage. Control LTA was performed 5 days after therapeutic adjustments. The intra- 
and inter-assay CVs of 5 μM induced aggregation were 7.98% and 3.34%, respectively. 
 
3.1.3. Patient follow-up 
Patients were re-interviewed and repeated LTA was performed at 6 and 12 month. The 
investigators were in close contact with the patients during the study period; patients 
were fully informed about the importance of the applied antiplatelet therapy and were 
asked to report modifications of their medication. The number of participants gradually 
decreased at the consecutive control points: at 6 month 102 MI and 48 SCAD patients 
were available for control LTA testing and interviewing. At 12 month 91 MI and 44 
SCAD patients completed the study. 
3.2. Determining factors of high on-treatment platelet reactivity in patients with 
acute coronary syndrome 
3.2.1. Patient population and study design 
In this study, we enrolled 463 consecutive ACS patients referred for urgent coronary 
angiography. Indications were as follows: 334 cases with ST segment elevation 
myocardial infarction (STEMI), 110 patients with non-ST segment elevation myocardial 
infarction (NSTEMI) and 19 cases with unstable angina (UAP). 95.9% of the population 
underwent percutaneous coronary intervention and 93.9% had coronary stent 
implantation. Exclusion criteria were history of cerebrovascular disease (transient 
ischemic attack or stroke), history of major gastrointestinal bleeding and 
contraindication to P2Y12 inhibitor treatment. Acetylsalicylic acid loading and 
maintenance treatment was applied according to current guidelines [48]. A single 
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loading dose of 600 mg clopidogrel was given to all patients prior to or at the time of 
angiography/PCI.  
 Use of glycoprotein IIb/IIIa receptor (GPIIb/IIIa) inhibitors was left to 
operator’s discretion. GPIIb/IIIa inhibitor applied was eptifibatide exclusively. 
Unfractionated heparin was administered for both diagnostics and percutaneous 
coronary intervention (70 IU/kg bolus for diagnostics and PCI with planned use of a 
GPIIb/IIIa inhibitor or 100 IU/kg bolus for PCI without planned use of a GPIIb/IIIa 
inhibitor). Coronary angiography and percutaneous coronary intervention were then 
performed using standard techniques. The study protocol was approved by the 
institutional ethics committee on human research and was conducted according to the 
principles of the Declaration of Helsinki. 
3.2.2. Platelet function testing 
Platelet function was measured in whole blood with multiple electrode aggregometry 
(Multiplate analyzer, Roche, Basel, Switzerland) 12 to 36 hours after 600 mg 
clopidogrel loading. When the GPIIb/IIIa inhibitor eptifibatide was applied during the 
PCI, based on the pharmacokinetic features of the drug, platelet function test was 
postponed to ensure a 24-hour time lag from cessation of eptifibatide administration. 
Measurement details were described previously [85]. Briefly, blood was drawn from the 
antecubital vein into hirudin-anticoagulated tubes (specified concentration >15 µg/mL). 
All samples were stored at room temperature and rested at least 30 minutes before the 
measurement as advised by the manufacturer. After twofold dilution with 0.9% w/v 
saline, samples were stirred for 3 minutes in the test cuvettes at 37°C. Then platelet 
agonist adenosine-diphosphate (ADP) was added at 6.4 μM final concentration. 
Increasing impedance is transformed to arbitrary aggregation units and is plotted against 
time continuously for 6 minutes. Platelet aggregation defined with MEA is quantified as 
area under the curve (AUC) of arbitrary aggregation units (U). The definition of high 
on-clopidogrel-treatment platelet reactivity (HPR) was based on the consensus paper of 
the Working Group on On-Treatment Platelet Reactivity, using >46 U as the cut-off 
value [77]. Below this threshold, platelet inhibition was considered to be efficient (no 
HPR). Platelet function testing was measured by an assistant who was blinded to patient 
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clinical characteristics and laboratory measurements. Investigators making statistical 
analyses were not involved in the data acquisition. 
3.2.3. Other laboratory measurements 
Hematology testing was performed on a Sysmex XE 2100 analyzer (Sysmex Europe 
GmbH, Hamburg, Germany). Blood glucose and high sensitive C-reactive protein (hs-
CRP) levels were measured by a Modular Analytics EVO Cobas 6000 analyzer (Roche, 
Basel, Switzerland), whereas troponin I was evaluated using Architect Stat high 
sensitive troponin I immunoassay (Abbott, Abbott Park, IL). All measurements were 
carried out according to manufacturers’ instructions. 
3.3. Statistical methods used in the studies 
Formal sample size calculations were not applied because all cohort studies are ongoing 
studies. Furthermore, for derivation studies of risk prediction models, there are no 
generally accepted approaches to estimate the sample size requirements. Analyses were 
performed on all data acquired during the study period. Categorical variables in 2×2 
contingency tables were assessed using Fisher’s exact test. Categorical data in 2×k 
contingency tables were analyzed using the unordered chi-squared test or, to detect 
linear trend, the Cochran-Armitage test (chi-squared test for trend). Continuous 
parameters were examined for normality with the Shapiro-Wilks W and the D’Agostino 
Pearson test. As none of the investigated continuous variables showed normal 
distribution, the Mann–Whitney test was applied for inter-group comparisons. The 
Wilcoxon signed-rank test or repeated measures ANOVA test was used for repeated 
measures. To adjust for differences in demographic data between patients with stable 
coronary artery disease and myocardial infarction, ANCOVA analysis was used. 
Adjustment was performed for the following covariates: age, gender, BMI, smoking, 
hypertension, diabetes mellitus, hypercholesterolemia, elapsed time between clopidogrel 
loading and platelet function testing, history of myocardial infarction, previous PCI or 
CABG operation, aspirin and clopidogrel medication on admission.  
For the risk prediction model construction, logistic regression analysis was used. 
Presence of non-linear relationships of the continuous variables to log odds of HPR 
were explored using restricted cubic splines which were then evaluated graphically and 
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by formal Wald testing for linearity. Since none of the continuous predictors showed 
non-linear association with the log odds of the outcome, they were used as linear 
variables. Univariate logistic regression analysis was performed to identify parameters 
with a p value less than 0.2. These variables were entered into a backward multivariate 
logistic regression model. Clinical parameters that were previously found to be 
associated with HPR, such as BMI, diabetes mellitus and renal function were forced 
into the multivariate model irrespective of the univariate p value. In multivariate logistic 
regression, parameters with a p value above 0.1 on likelihood ratio testing were then 
sequentially removed. The likelihood ratio and the Hosmer-Lemeshow tests were used 
to assess model fit, whereas predictive power was evaluated by receiver operating 
characteristic (ROC) curve analysis. To adjust for different scales of the predictors in 
the multivariate model, significance of individual parameters was assessed using the 
adequacy index, a parameter which indicates the proportion of the total explained 
variation in the outcome (expressed in terms of -2 log likelihood chi square) that could 
be explained by a single predictor [176]. Since the performance of a prediction model in 
the derivation dataset may overestimate the true performance, we conducted internal 
validation using 10,000 bootstrap samples to assess optimism. Risk of HPR was 
stratified as low, intermediate or high based on sensitivity, specificity and cumulative 
frequency distribution analyses of the predicted probability. For each of the risk classes, 
interval likelihood ratios were calculated. 
A two-tailed p value less than 0.05 was considered statistically significant. 
All analyses were carried out with MedCalc 15.2 (MedCalc Software, Ostend, 
Belgium, available at http://www.medcalc.org) except for linearity testing of continuous 
variables and internal validation, which were performed with R version 3.1.2 
(R Foundation for Statistical Computing, Vienna, Austria, available at http://www.R-
project.org) using the ‘rms’ package 4.2-1 (authored by Frank E Harrell Jr, available at 
http://biostat.mc.vanderbilt.edu/rms). 
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4. RESULTS 
4.1. Monitoring and optimizing antiplatelet therapy in patients with myocardial 
infarction and stable coronary artery disease 
Our first prospective study was conducted in patients with myocardial infarction 
(N=133) and stable coronary artery disease (N=67) undergoing percutaneous coronary 
intervention at our institute. 
4.1.1. Patient characteristics 
Baseline characteristics of the different patient groups are listed in Table 9. Age, 
prevalence of hypertension, hypercholesterinaemia, previous myocardial infarction, 
percutaneous coronary intervention and coronary artery bypass graft operation was 
significantly higher in the SCAD group, while ratio of smokers was higher in the MI 
group. Previous ACEI, beta-blocker, statin, aspirin and clopidogrel medication was 
significantly higher in the SCAD group. 
 Regarding initial P2Y12 inhibitor therapy, in the MI group, 41 patients (30.8%) 
were on standard 75 mg clopidogrel maintenance dose and 92 individuals (69.2%) were 
on 150 mg, high dose clopidogrel (according to our current institutional practice, see 
above). In the SCAD group all patients were on standard clopidogrel therapy at start 
(Table 9). 
Table 9. Demographic, clinical, and procedural characteristics of the MI and SCAD patients. 
Variable MI 
(n = 133) 
SCAD 
(n = 67) 
p Value* 
Age, years, median (IQR) 59 (51-66) 66 (59-73) <0.0001 
Female, % 32.6  34.3  0.87 
BMI, kg/m2, median (IQR) 27.7 (24.9-31.1) 27.4 (24.9-30.0) 0.32 
Medical history    
Hypertension, % 65.2 85 <0.01 
Diabetes mellitus, % 26.7 35.8 0.25 
Dyslipidaemia, % 22.9 47.8 <0.001 
History of tobbacco use, % 57.9 28.4 <0.001 
Previous myocardial infarction, % 11.1 32.8 <0.001 
Previous PCI, % 16.3 44.8 <0.0001 
Previous CABG, % 0.0 13.4 <0.0001 
DOI:10.14753/SE.2016.1919
39 
 
Medication on admission    
Acetylsalycilic acid, % 22.9 82.1 <0.0001 
Clopidogrel, % 7.4 47.8 <0.0001 
ACEI or ARB, % 44.4 91 <0.0001 
β-blocker, % 36.3 76.1 <0.0001 
Nitroglycerin, % 16.3 50.7 <0.0001 
Lipid lowering agents, % 26.7 89.6 <0.0001 
 
PPI medication at baseline 
   
On PPI, % 91 53.7 <0.0001 
Pantoprazole, %  91 50.7 <0.0001 
Lansoprazole, %  0.0 1.5 0.34 
Rabeprazole, % 0.0 1.5 0.34 
Procedural parameters    
Number of diseased vessels (%) 
1 
2 
3 or left main artery 
 
48.9 
25.9 
25.2 
 
50.7 
29.9 
19.4 
 
1.00 
0.62 
0.38 
Number of implanted stents, median (IQR) 1 (1-2) 1  (1-2) 0.46 
Total stent length, mm, median (IQR) 32 (24-50) 28 (20-48) 0.23 
Clopidogrel maintenance dose at baseline, %    
75 mg 30.8 100 <0.0001 
150 mg 69.2 0 <0.0001 
ACEI: angiotensin-converting enzyme inhibitor, ARB: angiotensin II receptor blocker, BMI: body mass 
index, CABG: coronary artery bypass graft surgery, IQR: interquartile range, MI: myocardial infarction, 
PCI: percutaneous coronary intervention, PPI: proton pump inhibitor, SCAD: stable coronary artery 
disease. Highlighted rows indicate statistical significance. * p values were calculated with the Mann-
Whitney (continuous parameters) and the Fisher’s exact (categorical parameters) tests. 
4.1.2. Baseline platelet aggregations in the MI and SCAD patients 
Baseline platelet reactivity in respect to most agonists was significantly higher in 
patients receiving 75 mg clopidogrel in the MI group than in the SCAD group (detailed 
demographic description and aggregation values of these subgroups are shown in Table 
10).  
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Table 10. Demographic data and baseline platelet reactivity of SCAD and MI patients on 75 mg 
clopidogrel. 
Variable MI on 75 mg 
clopidogrel 
(n = 41) 
SCAD 
(n = 67) 
p 
value* 
Age, years, median (IQR) 66 (57-72) 66 (59-73) 0.36 
Female, % 48.8 34.3 0.16 
BMI, kg/m2, median (IQR) 25.7 (23.1-30.1) 27.4 (24.9-30) 0.16 
Medical history    
Hypertension, % 68.3 85.0 0.05 
Diabetes mellitus, % 21.9 35.8 0.14 
Dyslipidaemia, % 17.1 47.8 <0.01 
History of tobbacco use, % 48.8 28.4 0.04 
Previous myocardial infarction, % 12.2 32.8 0.02 
Previous PCI, % 14.6 44.8 <0.01 
Previous CABG, % 0.0 13.43 0.01 
Medication on admission    
Acetylsalycilic acid, % 26.8 82.1 <0.0001 
Clopidogrel, % 9.8 47.8 <0.0001 
ACEI or ARB, % 51.2 91.0 <0.0001 
β-blocker, % 41.5 76.1 <0.001 
Nitroglycerin, % 9.8 50.7 <0.0001 
Lipid lowering agents, % 29.3 89.6 <0.0001 
Procedural parameters    
Number of diseased vessels (%) 
1 
2 
3 or left main artery 
 
41.5 
34.1 
24.4 
 
50.7 
29.9 
19.4 
 
0.43 
0.67 
0.63 
Number of implanted stents, median (IQR) 2 (1-2) 1  (1-2) 0.33 
Total stent length, mm, median (IQR) 35 (28-46)   28 (20-48) 0.24 
Baseline platelet reactivity, MA %, 
median (IQR) 
   
1 µg/ml collagen 20 (12-31.5) 18.5 (10-35.5) 0.70 
1,25 µM ADP  16 (9.8-25) 8 (2.3-15) <0.001 
5 µM ADP 43 (36-53) 39 (28-48) 0.02 
10 µM ADP 54 (45.8-62.3) 46 (35.3-56.8) <0.01 
10 µM epinephrine 43 (30-59) 24 (17-46.8) <0.01 
0,5 µg/ml arachidonic acid 4 (1.8-6.3) 2 (1-4.8) 0.01 
ACEI: angiotensin-converting enzyme inhibitor, ADP: adenosine-diphosphate, ARB: angiotensin II 
receptor blocker, BMI: body mass index, CABG: coronary artery bypass graft surgery, IQR: interquartile 
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range, MA: maximal aggregation, MI: myocardial infarction, PCI: percutaneous coronary intervention, 
PPI: proton pump inhibitor, SCAD: stable coronary artery disease. * p values were calculated with the 
Mann-Whitney (continuous parameters) and the Fisher’s exact (categorical parameters) tests. 
 
After adjustment to demographic parameters, the difference diminished in case of 
epinephrine and arachidonic-acid induced aggregations (p=0.359 and p=0.861, 
respectively), however, the difference remained significant with all concentrations of 
the ADP agonist (1.25ADP: p=0.005; 5ADP: p=0.046; 10ADP: p=0.023; Figure 4).  
 
 
Figure 4. Baseline platelet reactivity of MI and SCAD patients being on identical 75 mg clopidogrel 
therapy. In the MI group platelet reactivity was significantly higher with all concentrations of ADP after 
adjustment for demographic differences. Results are expressed as mean (represented by columns) ± SEM 
(represented by bars). p<0.05 was considered significant.  
Interestingly, patients receiving 150 mg clopidogrel compared to those taking 
the standard dose within the MI group, showed only a tendency of lower platelet 
reactivity, without reaching statistical significance. Moreover, after adjusting to 
demographic parameters, this tendency completely diminished regarding all agonists 
(Figure 5).  
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Figure 5. Platelet reactivity at baseline in the 75 mg and 150 mg clopidogrel subgroups of MI 
patients. After adjustment for covariates no difference was observed between the two subgroups. Results 
are expressed as mean (represented by columns) ± SEM (represented by bars). p<0.05 was considered 
significant. 
Detailed characteristics of patient subgroups and aggregation values are shown in Table 
11. 
Table 11. Demographic data and baseline platelet reactivity of MI patients on 75 and 150 mg clopidogrel. 
Variable MI on 75 mg clo 
n = 41 
MI on 150 mg clo 
n = 92 
 
p value* 
Age, years, median (IQR) 66 (57-72) 56 (50-64) <0.001 
Females, % 48.8 25  0.01 
BMI, kg/m2, median (IQR) 25.7 (23.1-30.1) 28.5 (25.9-31.9) <0.01 
Medical history    
Hypertension, % 68.3 64.1 0.70 
Diabetes mellitus, % 21.9 29.3 0.41 
Dyslipidaemia, % 17.1 26.1 0.37 
History of tobacco use % 48.8 61.9 0.18 
Previous myocardial infarction, % 12.2 10.9 0.76 
Previous PCI, % 14.6 16.3 1.00 
DOI:10.14753/SE.2016.1919
43 
 
Previous CABG, % 0.0 0.0 NE 
Medication on admission    
Aspirin, %  26.8 20.7 0.50 
Clopidogrel, %  9.8 6.5 0.50 
ACEI or ARB, % 51.2 56.5 0.58 
β-blocker, % 41.5 33.7 0.44 
Nitroglycerine, % 9.8 10.9 1.00 
Lipid-lowering agents, % 29.3 25 0.67 
Procedural parameters    
Number of diseased vessels % 
               1 
               2 
               3 or LM 
 
41.5 
34.1 
24.4 
 
52.2 
22.8 
25 
 
0.27 
0.20 
1.00 
Number of implanted stents, median (IQR) 2 (1-2) 1 (1-2) 0.50 
Total stented length (mm), median (IQR) 35 (28-46)   31.5 (24-53.5) 0.47 
Baseline platelet reactivity, MA %,  
median (IQR)  
   
1 µg/ml collagen 20 (13-30) 25 (12.5-44.5) 0.40 
1,25 µM ADP  16 (10-25) 12 (6-21) 0.14 
5 µM ADP 43 (36-53) 39 (29.5-50) 0.07 
10 µM ADP 54 (46-62) 48 (37-59) 0.09 
10 µM epinephrine 43 (30-58) 34.5 (20-55) 0.08 
0,5 µg/ml arachidonic acid 4 (2-6) 3 (1-7) 0.67 
ACEI: angiotensin-converting enzyme inhibitor, ADP: adenosine-diphosphate, ARB: angiotensin II 
receptor blocker, BMI: body mass index, CABG: coronary artery bypass graft surgery, IQR: interquartile 
range, MA: maximal aggregation, MI: myocardial infarction, NE: not evaluated because of insufficient 
data, PCI: percutaneous coronary intervention, PPI: proton pump inhibitor, SCAD: stable coronary artery 
disease. * p values were calculated with the Mann-Whitney (continuous parameters) and the Fisher’s 
exact (categorical parameters) test. 
4.1.3. Definition and ratio of high on-clopidogrel platelet reactivity based on LTA 
results in MI and SCAD patients 
5 μM ADP induced maximal aggregation (AGGRmax 5ADP) was considered as the 
indicator of the efficacy of clopidogrel therapy with the cut-off value of 
AGGRmax 5ADP>50 %. Above this value high on-clopidogrel platelet reactivity 
(HCPR), below this value no high on-clopidogrel platelet reactivity (no HCPR) was 
identified, independently of the applied clopidogrel maintenance dose. 
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The number of patients with high platelet reactivity tended to be higher in the 
MI than in the SCAD group (MI: 19.5% vs SCAD: 11.9%; p=0.232). Similarly to the 
baseline platelet aggregation data, proportion of HCPR patients within the MI group 
tended to be higher among patients on 75 mg maintenance dose compared to those 
being on 150 mg  (26.8% vs. 16.3%, p=0.164). 
4.1.4. Definition, ratio and management of clopidogrel pseudo and real non-responders 
In HPR patients, antiplatelet therapy was adjusted as follows: in case of 75 mg 
clopidogrel, the drug dose was doubled. In patients with HPR already on 150 mg 
clopidogrel, 2x250 mg ticlopidine was induced, as the study was conducted before the 
prasugrel/ticagrelor era (patient management and therapeutic modifications are 
indicated in Figure 6). 
Patients with high initial platelet reactivity on 75 mg but reaching normal 
platelet reactivity on 150 mg clopidogrel were defined as clopidogrel pseudo non-
responders (PsNR). In contrast, patients with persisting high platelet reactivity even on 
150 mg clopidogrel were defined as clopidogrel real non-responders (RNR, Figure 6). 
The ratio of real non-responders was significantly higher in the MI group 
compared to SCAD group (MI: 18/133=13.5% vs SCAD: 2/67=2.9%; p=0.023). The 
ratio of pseudo non-responders also tended to be higher in the MI group but did not 
reach statistical significance (MI: 8/41=19.5% vs SCAD: 6/67=8.9%, p=0.143, Figure 
6). 
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Figure 6. Classification, platelet reactivity and antiplatelet management of the MI and SCAD 
patient groups. Initial clopidogrel therapy, number of patients with HCPR, therapy modification and 
ratio of pseudo and real clopidogrel non-responders are shown in the MI and SCAD group at baseline, 6 
month and 12 month. AGGR5ADP: maximal 5µM ADP induced aggregation by LTA, clo: clopidogrel, 
HCPR: high on-clopidogrel platelet reactivity, MI: myocardial infarction, PsNR: pseudo non-responder, 
RNR: real non-responder, SCAD: stable coronary artery disease, TIC: ticlopidine.  
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4.1.5. Functional results of antiplatelet therapy modification 
In pseudo non-responders clopidogrel dose doubling resulted in effective platelet 
inhibition. On the other hand, switch of therapy to ticlopidine also resulted in normal 
platelet reactivity in all patients in the SCAD group and in the majority of real non-
responders in the MI group (16 out of 18 individuals, Figure 6). Platelet reactivity in MI 
and SCAD patients before and after therapy adjustment or switch is shown in Figure 7. 
Patients undergoing therapy intensification remained on modified therapy for the whole 
study period. 
 
 
Figure 7. Platelet reactivity after modification of therapy in clopidogrel pseudo non-responders 
(PsNR) in the MI (A) and in the SCAD (B) group and in clopidogrel real non-responders (RNR) in 
the MI (C) and SCAD group (D). Clopidogrel dose doubling in PsNR patients resulted in significantly 
lower platelet aggregation induced by ADP in both patient groups (A and B). Platelet reactivity induced 
by collagen, epinephrine and arachidonic-acid also tended to be lower in PsNR patients. Platelet reactivity 
was significantly lower after ticlopidine induction induced by all agonists in RNR patients in the MI 
group (C) and was also substantially lower induced by ADP in the SCAD group (D, statistical analysis 
was not performed because of low case number). Results are expressed as median (represented by 
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squares), IQR (represented by boxes) and non-outlier range (represented by bars). p<0.05 was considered 
significant. 
4.1.6. Long term follow-up of platelet function in MI and SCAD patients 
In the MI group most of the patients (n=84) were already on standard 75 mg clopidogrel 
therapy by 6 month, however 8 patients received 150 mg clopidogrel and 10 patients 
received ticlopidine as a result of therapy intensification (Figure 6). At 12 month, 60 
patients were on standard, 5 patients were on high dose clopidogrel and 10 patients were 
on ticlopidine. Platelet reactivity remained on the same level throughout 12 months 
follow-up in the MI group (Figure 8A). 
In the SCAD group 44 patients were on standard, 2 patients were on high dose 
clopidogrel and 2 patients were on ticlopidine at 6 month. At 12 month, 38 patients on 
75 mg, 1 patient on 150 mg clopidogrel and 1 patient on ticlopidine were available for 
retesting (Figure 6).  In SCAD patients, platelet reactivity showed slight oscillation: at 6 
months platelet aggregation was significantly higher compared to the 12 month values 
(5ADP6month vs. 5ADP12month p=0.005; Figure 8B). 
Platelet reactivity did not differ between the MI and SCAD group at 6 and 12 
month and was also irrespective of the 75 mg or 150 mg clopidogrel maintenance 
therapy at 6 and at 12 months (data not shown). 
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Figure 8. Long term follow-up results of platelet reactivity in MI (A) and SCAD (B) patients. In the 
MI group (N=71), platelet function remained approximately the same throughout 12 month follow-up 
period. In SCAD patients (N=39), platelet function showed modest oscillation during 12 month follow-
up. At 6 month platelet reactivity tended to be higher compared to the baseline values and proved to be 
significantly higher than platelet reactivity at 12 month. Results are expressed as median (represented by 
squares), IQR (represented by boxes) and non-outlier range (represented by bars). p<0.05 was considered 
significant. 
4.1.7. Incidence of new HCPR during 12 month follow-up in MI and SCAD patients 
Despite the fact, that out of our 200 patients, 198 individuals were on effective 
antiplatelet therapy after modifications at baseline, there was a remarkable incidence of 
new HCPR at 6 month in both patient groups (Figure 9).  
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Figure 9. Individual platelet aggregation values induced by 5 M ADP at baseline, 6 and 12 month 
in the MI (A) and in the SCAD (B) group. Patients were represented by separate dots and lines. To 
declare high on-treatment platelet reactivity, we used the AGGRmax 5ADP=50% cut-off value. There were a 
remarkable number of patients returning with HCPR at both measuring times in both patient groups. The 
incidence of new HCPR at 6 month is higher in the SCAD group, than in the MI group (in correlation 
with platelet function kinetics, Figure 8). In some patients, HPR persisted from 6 to 12 month in both 
groups. However, there were HCPR patients at 6 month who returned with normal platelet reactivity at 12 
month without any therapeutic adjustment.  
 
In the MI group new HCPR occurred in 12 patients receiving standard and in 2 
patients receiving high dose clopidogrel therapy (13.7%, Figure 6). Interestingly, in the 
SCAD group incidence of new HCPR was unexpectedly high; 14 patients were on 75 
mg and 1 patient was on 150 mg clopidogrel (Figure 6). 
In these patients, further therapeutic interventions were not performed. 
Interestingly, the majority of patients with HCPR at 6 month, returned with normal 
platelet reactivity at 12 month (MI group: 8 patients on 75 mg and 1 patient on 150 mg 
clopidogrel; SCAD group: 11 patients on 75 mg and 1 patient on 150 mg clopidogrel). 
Nevertheless, HCPR persisted from 6 to 12 month in 4 patients being on 75 mg and 1 
patient being on 150 mg clopidogrel in the MI group. Persisting HCPR from 6 to 12 
month was also observed in 3 SCAD patients receiving 75 mg clopidogrel. 
By 12 month, new HCPR was observed in 8 MI patients being on standard 
clopidogrel therapy and no further incidence of HCPR was observed on high dose 
clopidogrel therapy. The ratio of new HCPR at 12 month was substantially lower in the 
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SCAD group: only 1 patient on 75 mg clopidogrel returned with new HCPR and no 
further incidence of HCPR was observed on high dose clopidogrel therapy (Figure 6). 
Interestingly, all clopidogrel real non-responders switched over to ticlopidine 
remained effectively inhibited during the whole follow-up period. 
4.1.8. Clinical end points during 12 month follow up 
During the study we documented clinical efficacy and safety endpoints (Table 12). The 
12 month cumulative event rate was 8.3% in the MI and 1.5% in the SCAD group. 
During the 12 month follow-up no TIMI major or minor bleeding events were 
documented. 
 
Table 12. Clinical outcome data during 12 month follow-up. 
End point MI (n = 133)   SCAD (n = 67) 
Death from any cause n 4 1 
Stroke n 1 0 
Reinfarction  n 0 0 
Urgent revascularization  n 2 0 
Non-urgent target vessel revascularization n 4 0 
Stent thrombosis  n 0 0 
TIMI minor bleeding  n 0 0 
TIMI major bleeding  n 0 0 
 
4.2. Determining factors of high on-treatment platelet reactivity in patients with 
acute coronary syndrome 
In a second prospective cohort study, we investigated the predictors of HCPR measured 
by the point-of-care multiple electrode aggregometry. 
4.2.1. Patient characteristics  
Demographic, clinical, and procedural characteristics of the overall population of 463 
patients and the subgroups with or without HPR are summarized in Table 13. Most of 
the parameters were similar in the HPR and no HPR groups. However, platelet count 
(PLT) and high sensitive C-reactive protein level measured upon admission were 
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statistically higher in the HPR group (Fisher’s exact test, p=0.01 and p=0.02, 
respectively). 
Table 13. Demographic, Clinical, and Procedural Characteristics. 
Variable Overall 
(n = 463) 
No HCPR 
(n = 389) 
HCPR 
(n = 74) 
p Value* 
Platelet reactivity, U, median (IQR) 
29.0  
(21.0-39.0) 
27.0  
(20.0-34.0) 
56.5  
(50.0-62.0) 
<0.0001 
Age, years, median (IQR) 
61.0  
(52.0-69.0) 
61.0  
(52.0-68.0) 
60.5  
(52.0-70.0) 
0.55 
Female, % 28.7 27.0 37.8 0.07 
BMI, kg/m2, median (IQR) 
28.0  
(25.0-31.0) 
28.0  
(25.0-31.0) 
28.0  
(26.0-31.0) 
0.38 
LVEF, %, median (IQR) 
51.0  
(43.0-59.0) 
51.0  
(44.0-59.0) 
50.0  
(40.0-57.0) 
0.32 
Medical history     
Hypertension, % 63.5 64.5 58.1 0.30 
Diabetes mellitus, % 25.1 24.7 27.0 0.66 
Dyslipidaemia, % 19.4 19.0 21.6 0.63 
Current smoker, % 39.1 40.9 29.7 0.09 
Previous myocardial infarction, % 13.6 13.6 13.5 1.00 
Previous PCI, % 15.6 15.2 17.6 0.60 
Previous CABG, % 2.6 2.6 2.7 1.00 
Congestive heart failure, % 12.3 11.8 14.9 0.44 
Peripheral artery disease, % 3.2 3.9 0.0 0.14 
Thyroid dysfunction, % 5.2 5.4 4.1 0.78 
Chronic kidney disease, % 18.4 19.3 13.5 0.32 
Concomitant medication     
Acetylsalycilic acid, % 98.7 98.7 98.6 1.00 
ACEI or ARB, % 88.6 89.2 85.1 0.32 
Aldosterone receptor antagonist, % 27.2 26.0 33.8 0.20 
β-blocker, % 89.2 89.7 86.5 0.42 
Calcium channel blocker, % 6.5 6.9 4.1 0.45 
Nitroglycerin, % 23.8 23.4 25.7 0.66 
Statin, % 91.6 92.0 89.2 0.49 
Proton pump inhibitor, % 93.7 93.3 95.9 0.60 
Oral anti-diabetic, % 18.4 17.5 23.0 0.26 
Insulin, % 6.7 6.2 9.5 0.31 
Laboratory values upon admission     
RBC count, T/L, median, (IQR) 4.7 (4.3-5.0) 4.7 (4.3-5.0) 4.7 (4.5-5.0) 0.96 
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Hemoglobin, g/L, median, (IQR) 
141.0  
(130.0-152.0) 
142.0  
(130.0-152.0) 
141.0  
(128.0-151.0) 
0.25 
Hematocrit (IQR) 
0.41  
(0.38-0.44) 
0.41  
(0.38-0.44) 
0.41  
(0.38-0.44) 
0.89 
WBC count, G/L, median, (IQR) 
10.2  
(8.3-12.9) 
10.0  
(8.3-12.5) 
10.8  
(8.4-13.6) 
0.13 
Platelet count, G/L, median, (IQR) 
236.0  
(198.3-282.8) 
232.0  
(195.0-281.3) 
250.5  
(221.0-310.0) 
0.01 
MPV, fL, median, (IQR) 
10.8  
(10.2-11.4) 
10.8  
(10.2-11.4) 
10.7  
(10.3-11.2) 
0.46 
CRP, mg/L, median, (IQR) 4.4 (2.2-11.2) 4.1 (2.1-10.6) 7.4 (2.6-24.4) 0.02 
Glucose, mmol/L, median, (IQR) 7.0 (5.9-8.8) 6.9 (5.9-8.6) 7.2 (6.0-9.2) 0.38 
Troponin I, ng/mL, median, (IQR)† 1.9 (0.4-9.8) 1.9 (0.4-9.8) 1.8 (0.6-10.1) 0.69 
Troponin I, categorical, % 
TnI < 0.3 mg/mL 
0.3 ng/mL ≤ TnI ≤ 50.0 ng/mL 
TnI > 50.0 ng/mL 
 
21.6 
72.4 
6.0 
 
21.9 
73.0 
5.1 
 
20.3 
68.9 
10.8 
0.26 
 
 
 
Procedural parameters     
Indication for angiography (%) 
STEMI 
NSTEMI 
UAP 
 
72.1 
23.8 
4.1 
 
71.7 
24.4 
3.9 
 
74.3 
20.3 
5.4 
0.65 
 
 
 
Number of diseased vessels (%) 
1 
2 
3 or left main artery 
 
39.1 
30.0 
30.9 
 
38.6 
30.1 
31.4 
 
41.9 
29.7 
28.4 
0.55 
 
 
 
Therapeutic modality, % 
POBA / thrombus aspiration only 
BMS implantation 
DES implantation‡ 
CABG 
Medical therapy only 
 
1.9 
76.0 
17.9 
1.1 
3.0 
 
2.1 
76.1 
17.5 
1.0 
3.3 
 
1.4 
75.7 
20.3 
1.4 
1.4 
0.86 
 
 
 
 
 
Number of implanted stents, % 
1 
2 
3 
4 
5 
 
58.7 
30.5 
7.6 
2.1 
1.1 
 
58.1 
30.4 
7.9 
2.2 
1.4 
 
62.0 
31.0 
5.6 
1.4 
0.0 
0.26 
 
 
 
 
 
Total stent length, mm, median (IQR) 
33.0  
(23.0-50.0) 
33.0  
(22.3-49.3) 
36.0  
(23.3-50.0) 
0.96 
Mean stent diam., mm, median (IQR) 3.0 (2.8-3.3) 3.0 (2.8-3.3) 3.0 (2.8-3.2) 0.30 
Use of GPIIb/IIIa receptor inhibitor (%) 52.1 52.2 51.4 0.89 
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, 
body mass index; BMS, bare metal stent; CABG, coronary artery bypass graft surgery; CRP, C-reactive 
protein; DES, drug eluting stent; diam., diameter; GPIIb/IIIa, glycoprotein IIb/IIIa; IQR, interquartile 
range; LVEF, left ventricular ejection fraction; MPV, mean platelet volume; NSTEMI, non-ST-segment 
elevation myocardial infarction; PCI, percutaneous coronary intervention; POBA, plain old balloon 
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angioplasty; HCPR, high on-clopidogrel platelet reactivity; RBC, red blood cell; STEMI, ST-segment 
elevation myocardial infarction; TnI, troponin I; UAP, unstable angina pectoris; WBC, white blood cell. 
* p values refer to differences between the HPR and no HPR groups. 
† values within detection limits: 0.01 ng/mL < TnI ≤ 50.0 ng/mL. 
‡ implantation of at least one DES with or without parallel BMS placement. 
 
4.2.2. Distribution of platelet aggregation values measured by MEA 
The ADP-induced-platelet aggregation units (U) of the overall population showed a 
right-skewed, unimodal distribution with a median (M) of 29.0 U (IQR 21.0 to 39.0 U, 
Figure 10). Based on the >46 U cut-off value, the proportion of HCPR was 
74/463=16.0%. The median platelet aggregation values in the HCPR and no HCPR 
groups were 56.5 U (IQR 50.0 to 62.0 U) and 27.0 U (IQR 20.0 to 34.0 U), respectively, 
Table 1. The ADP induced aggregation values did not differ in the GPIIb/IIIa inhibitor 
treated and untreated groups (M: 30 U, IQR: 22.0 to 40.0 U vs. M: 29 U, 
IQR: 20.0 to 39.0 U, p=0.31). 
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Figure 10. Distribution of ADP-induced platelet aggregation values measured by MEA. The upper 
part of the figure demonstrates the distribution of aggregation values (U) in the entire population with 
single dots representing patients. The vertical orange line indicates the cut-off value of 46 U between 
patients with and without high on-treatment platelet reactivity. The lower part of the figure shows the 
histogram of ADP-induced aggregation values in the overall population. 
4.2.3. Factors related to HCPR, model construction 
Univariate logistic regression analysis was performed to all parameters listed in 
Table 13. Variables univariately associated with HCPR with a p value less than 0.2 were 
as follows: PLT count (per G/L, p=0.0006), white blood cell count (WBC, per G/L, 
p=0.06), CRP level (per mg/L, p=0.03), troponin I level >50 ng/mL (p=0.07) upon 
admission, female gender (p=0.06) and non-smoking status (p=0.07). These factors and 
clinical parameters that were previously found to be associated with HCPR, such as 
diabetes mellitus, BMI and renal function were entered into the backward multivariate 
logistic regression model. Based on the analysis, PLT count (per G/l, odds ratio 
[OR]: 1.0073, 95% confidence interval [95% CI]: 1.0035 to 1.0112, p=0.0002), CRP 
level (per mg/L, OR, [95% CI]: 1.0077 [1.0016 to 1.0137], p=0.01) upon admission, 
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and current smoking (OR [95% CI]: 0.51 [0.29 to 0.89], p=0.02) proved to be predictors 
of HCPR (Table 14). According to the adequacy index, PLT count was the most 
powerful variable, while CRP level and active smoking had less pronounced effects 
(Table 14). 
 
Table 14. Multivariate Predictors of High Platelet Reactivity. 
Variable Adequacy Coefficient Standard 
error 
OR 95% CI p Value 
Platelet count, 
per G/L 
0.52 0.0073 0.0019 1.0073 1.0035-1.0112 0.0002 
CRP, per mg/L 0.19 0.0076 0.0031 1.0077 1.0016-1.0137 0.0127 
Current smoking 0.15 -0.6747 0.2855 0.5093 0.2911-0.8912 0.0181 
Constant  -3.4020 0.5249   <0.0001 
CI indicates confidence interval; CRP, C-reactive protein; OR, odds ratio. 
 
The likelihood ratio and Hosmer-Lemeshow tests showed good model fit (p<0.0001 and 
p=0.43, respectively, Table 15).  
 
 
Table 15. Performance of the Risk Prediction Model. 
Parameter Value 
Overall model fit  
Null model -2 log likelihood 406.869 
Full model -2 log likelihood 384.257 
Chi-square 22.612 
Degree of freedom 3 
Significance level (p) <0.0001 
ROC curve analysis  
Area under the ROC curve 0.665 
Standard error 0.036 
95% Confidence interval 0.620-0.708 
Significance level (p) <0.0001 
Youden index  
Youden index J 0.307 
Associated criterion >0.167 
Sensitivity, % 59.5 
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Specificity, % 71.2 
Hosmer-Lemeshow test  
Chi-square 8.06 
Degree of freedom 8 
Significance level (p) 0.43 
ROC indicates receiver operating characteristic. 
 
The area under the ROC curve analysis revealed moderate predictive power 
(AUC=0.665, Figure 11). 
 
Figure 11. Discriminative capacity of the risk prediction model. The receiver operating characteristic 
curve analysis revealed moderate predictive power (AUC [95% CI]=0.67 [0.62 to 0.71], p<0.0001). 
 
4.2.4. Internal validation 
Since the performance of a model in the development dataset may overestimate the true 
performance, we conducted internal validation using 10,000 bootstrap samples. 
Predictive accuracy was characterized by the AUC value while calibration was assessed 
by means of the intercept and slope of the calibration line, as proposed by Cox[177]. 
Moreover, we evaluated calibration graphically by applying a LOWESS smoother on 
DOI:10.14753/SE.2016.1919
57 
 
scatterplots of predicted versus observed probabilities. Considering accuracy, optimism 
proved to be 0.013 resulting in an optimism-corrected AUC value of 0.653. Both the 
optimism-adjusted intercept and slope were on average correct (-0.102 and 0.930, 
respectively), not necessitating recalibration of the apparent model (Table 16, 
Figure 12). 
 
 
Figure 12. Calibration plot of the apparent and optimism-corrected models. Calibration curves were 
created using a LOWESS smoother on the scatterplot of expected versus observed risks. Differences 
between the predicted and actual event rates were small across the whole risk spectrum for the apparent 
model (Hosmer-Lemeshow test, p=0.43,). Internal validation using 10,000 bootstrap samples revealed 
only negligible optimism in calibration with a bias-corrected (validated) intercept of -0.102 and slope of 
0.930. Thus, recalibration of the apparent model was not necessary. The rug plots across the top of the 
figure show the distribution of the predicted risk. 
Table 16. Internal Validation of Predictive Accuracy and Calibration. 
 AUC Cox validation intercept Cox validation slope 
Apparent 0.665 0.000 1.000 
Optimism* 0.013 0.102 0.070 
Optimism-corrected* 0.653 -0.102 0.930 
AUC indicates area under the receiver operating characteristic curve. 
* Results are based on 10,000 bootstrap samples. 
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4.2.5. Risk stratification 
Based on sensitivity, specificity and cumulative frequency distribution analyses of the 
predicted probability, three risk classes (low, intermediate, and high risk) were defined. 
Table 17 gives details of the classification parameters, the proportion of patients in the 
classes, event rates, and interval likelihood ratios for each of these risk strata. Using this 
classification, low- and high risk patients, who represent some 60% of the population, 
may be precisely identified. There is more than a fourfold increase in post-test 
probability of HCPR between patients of the low- and high risk strata (8.7% versus 
35.7%). On the contrary, pre- and post-test probabilities are almost identical (16.0% 
versus 18.1%) in the intermediate risk group corresponding to some 40% of the cases. 
 
Table 17. Interval Likelihood Ratios According to Risk Strata. 
Risk class 
(predicted probability of 
HCPR) 
HCPR No HCPR Number / 
percent at 
risk 
Rate 
of 
HPR 
Interval 
likelihood 
ratio 
95% CI 
Low risk (≤0.13) 18 190 208 / 44.9% 8.7% 0.498 0.329-0.754 
Intermediate risk 
(>0.13 to ≤0.25) 
36 163 199 / 43.0% 18.1% 1.161 0.894-1.508 
High risk (>0.25) 20 36 56 / 12.1% 35.7% 2.920 1.795-4.752 
Overall 74 389 463 / 100% 16.0% NA NA 
HPR: high on-clopidogrel platelet reactivity; CI: confidence interval; NA: not applicable. 
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Using risk stratification, low, intermediate and high risk patients were successfully 
separated. As it is indicated in Figure 13, 95% confidence intervals of the interval 
likelihood ratios do not overlap each other suggesting clearly different levels of risk in 
the three strata.  
 
 
Figure 13. Interval likelihood ratios according to risk strata. Point estimates ranging from 0.50 to 2.92 
with non-overlapping 95% confidence intervals indicate clearly separated risk levels. 
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Also, with increasing risk class, there is a monotonic rise in the observed rates of high 
on-clopidogrel platelet reactivity (Cochran-Armitage test, p<0.0001, Figure 14). 
Moreover, differences between the predicted and actual event rates were small across 
the risk strata. 
 
 
Figure 14. Observed rate of high on-clopidogrel platelet reactivity across the risk strata. The rate of 
HPR showed monotonic increase throughout subsequent risk classes (Cochran-Armitage test, p<0.0001). 
There is a fourfold rise in probability of HPR between patients of the low- and high risk groups (8.7% 
versus 35.7%). Error bars represent exact binomial 95% confidence intervals. 
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5. DISCUSSION 
 
In the present work, we aimed to investigate the contribution of platelet function testing 
to treatment optimization and risk stratification of patients undergoing percutaneous 
coronary intervention.  
In our first study, we examined the efficacy of clopidogrel therapy with the gold 
standard “in vitro” platelet function test in order to identify patients with high on-
clopidogrel platelet reactivity with either acute or stable form of ischemic heart disease 
undergoing PCI. Thereafter gradual antiplatelet therapy adjustment was performed until 
reaching laboratory proven platelet inhibition. 
Platelet aggregation measured by light transmission aggregometry 
LTA is a cheap and reliable method in well-trained hands and under well-established 
circumstances and is successfully and widely used to monitor platelet reactivity in 
numerous laboratories [178]. Its predictive ability regarding ischemic events has already 
been well supported by several studies [73-75]. Importantly, in a large, comparative 
study investigating the association of different platelet function tests with clinical 
outcomes, it proved to be predictive to ischemic events during 12 months following PCI 
[76]. Moreover its predictive power regarding cardiac end points was at least 
comparable with that of the easily applicable point-of-care Verify Now method 
[179,180].  
With the use of LTA testing in our first 200 patients, we found that baseline 
platelet reactivity was significantly higher in patients with myocardial infarction than in 
patients with stable coronary artery disease. After adjusting for demographic variances 
between the patient groups (such as age, gender rate, BMI, smoking habits, occurrence 
of hypertension, diabetes mellitus, dyslipidaemia, history of myocardial infarction, 
previous PCI or CABG operation, elapsed time between clopidogrel loading and platelet 
function testing, and antiplatelet medication on admission), the difference remained 
significant with all concentrations of the ADP agonist. Our finding of higher platelet 
reactivity in myocardial infarction goes along well with the literature [81,181-184]. 
Importantly, our definition of HPR was also in good agreement with the current 
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recommendation of the platelet expert panel (5 µM ADP induced MA >46%) [180,185]. 
However, the initial ratio of HCPR in our overall patient population (17%) was lower 
than generally known from previous studies (even ≥ 50%) [125,186,187]. The cause in 
its background might have been the high proportion of our MI patients being on 150 mg 
clopidogrel initially. However, unexpectedly, the platelet reactivity in MI patients 
receiving 150 mg clopidogrel was approximately on the same level as that of the 
patients on standard clopidogrel dose. Its possible explanation might be the selection of 
patients in whom standard clopidogrel dose is presumably less effective by considering 
the clinical influencing factors of response variability (acute form of cardiac disease, 
younger age, higher BMI, higher frequency of comorbidities [38,186,188]) and 
successful treatment of this population with the double dose. In the CURRENT-OASIS 
7 study, administration of 150 mg clopidogrel in the first week in ACS patients treated 
with PCI was associated with a reduction in stent thrombosis compared with the 
standard dose [189]. This also supports our finding, that in lack of possibility to perform 
platelet function tests or to give prasugrel/ticagrelor (e.g. contraindication) the 
administration of 150 mg daily clopidogrel might be beneficial initially in high risk, 
acute cardiac patients selected by certain clinical parameters, because a portion of these 
patients have HPR beside 75 mg clopidogrel and need dose elevation to be effectively 
inhibited. 150 mg clopidogrel might also be a reasonable step in the gradual therapy 
intensification of MI patients if more potent drugs are contraindicated, as it may 
overcome HPR without increasing bleeding risk according to our observations and also 
supported by data from large clinical trials [84].  
Increased incidence of high on-clopidogrel platelet reactivity in the acute setting 
The ratio of HCPR even on 150 mg clopidogrel maintenance dose (clopidogrel real non-
responders) was significantly higher among the MI patients, suggesting that these 
invasively treated acute cardiac patients may benefit from prospective platelet function 
testing because of their higher atherothrombotic burden and widened antiplatelet 
treatment possibilities. Notably, in good agreement with our findings, the prevalence of 
HPR was shown to be higher in patients with acute coronary syndrome than in those 
with stable CAD in a large patient cohort [81]. In the recent years robust evidence 
supported the association of high on-treatment ADP induced platelet reactivity and 
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ischemic outcomes in different cardiology patient groups [73-75,87,167,190]. Accepting 
HPR as a clinically relevant factor, we need to investigate its modifiability and whether 
its optimization improves the outcome in different clinical settings. However, up to 
date, large clinical trials investigating the effect of tailored antiplatelet therapy on 
clinical outcome closed with neutral results [82-84,170]. Importantly, these studies used 
only one platelet function test (Verify Now) and agonist (ADP) to assess platelet 
function and were conducted in heterogeneous, but mostly elective and low-
intermediate risk patient populations. Also, there were great variances in terms of study 
designs, definitions of HPR, timing of platelet testing, and antiplatelet therapy 
modification algorithms as well as clinical endpoints and follow-up times. 
Consequently, there is a gap of knowledge regarding the role of platelet function testing 
and guided antiplatelet therapy in invasively treated ACS patients, especially in patients 
with STEMI, who are at the highest thrombotic risk. Furthermore, it cannot be 
excluded, that the use of other platelet function tests or use of more parallel agonists to 
compose a so-called „platelet reactivity index“ could be more sensitive in 
discriminating patients with HPR. Currently ongoing clinical trials (e.g. the 
TROPICAL-ACS, NCT01959451) will hopefully further expand our knowledge and 
will provide at least some of the lacking answers to these question. Also, more, 
carefully designed RCTs (e.g. parallel application of the most widely used PF tests, 
more homogeneous patient groups and therapy modification algorithms) are needed to 
gain additional information. 
Therapy modification results in effective platelet inhibition 
According to our repeated platelet function measurements, with switch of therapy (i.e. 
conversion to ticlopidine), we may overcome HCPR persisting even on 150 mg 
clopidogrel. This might be the result of different metabolic steps and enzymes being 
involved in the activation process of the distinct thienopyridines [45] (see also in the 
Introduction section, 1.2.1.2.). Interestingly, in patients with SCAD, therapy 
modification resulted in effective platelet inhibition in 100% of the patients; however 
optimal platelet inhibition could not be achieved even by therapy modification in a 
small portion of the MI patients with HCPR on 150 mg clopidogrel (2/19). It is likely, 
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however, that with switch to a novel, more potent agent even these patients would be 
efficiently treated. 
Appearance of new HCPR during long term follow-up 
There are relatively few and controversial data about long term platelet function kinetics 
[82-84]. In the TRILOGY-ACS platelet function substudy almost 50% of the patients 
on clopidogrel had HPR at the subsequent control points during 30 months follow up 
and the ratio of HPR patients proved to be stable over the time [191]. According to our 
results, platelet reactivity remained on the same level in the MI group throughout 12 
month and proved to be modestly oscillating in the SCAD group. However, a new 
appearance of HPR at 6 and 12 months was observed in both patient groups 
independently from the clopidogrel maintenance dose. This finding may have clinical 
consequences suggesting, that on clopidogrel treatment platelet reactivity - beside wide-
scale inter-individual variability - is not a stable parameter. It is determined by several 
clinical, genetic and cellular factors showing considerable alternation during follow-up 
[38,186,188]. Interestingly, platelet function in patients on clopidogrel altered in both 
directions spontaneously during long term follow up, contrarily induction of ticlopidine 
resulted in stable platelet inhibitory effect during 12 months follow-up. It also supports 
that clopidogrel’s effectiveness is very vulnerable and thienopyridines using other 
metabolization pathways may exert not only more extensive but more stable long-term 
platelet inhibitory effect [45]. Importantly, appearance of new HPR and inter-patient 
variability of platelet function –however to a smaller extent- was also described recently 
in prasugrel treated patients, particularly among patients on lower prasugrel 
maintenance dose [133,134]. Appearance of HPR may have clinical significance in 
patients with DES as their endothelial regeneration may be prolonged resulting in higher 
risk for late and very late stent thrombosis [192]. Therefore re-evaluation of platelet 
reactivity may be useful in patients with DES or before the performance of a subsequent 
percutaneous coronary intervention or to assess the efficacy of the maintenance dose of 
an antiplatelet drug. Therefore, the right approach to platelet function testing may 
include early assessment to assess drug effectivity and re-evaluation to judge dose 
effectivity or to adjust proper maintenance dose of an antiplatelet agent.  
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Safety considerations during intensified therapy 
In our patient population no TIMI major or minor bleeding consequences occurred in 
association with tailored antiplatelet therapy, which may suggest, that therapy 
intensification might be applied safely in a selected, well determined patient population. 
However re-evaluation of platelet function after modification of therapy might become 
desirable as there are data suggesting, that antiplatelet therapy intensification may 
increase bleeding risk in unselected patient population [41,42,189]. The ADAPT-DES 
study identified strong inverse relationship between high on-treatment platelet reactivity 
and clinically relevant bleeding as well as strong association of bleeding consequences 
with mortality; similar to that of stent thrombosis or myocardial infarction [193]. 
Consequently, increasing bleeding risk may counter-balance the favorable therapeutic 
effects of intensified platelet inhibition and beyond a given level may not improve 
survival - especially in low risk cardiac patients. Therefore, possible prediction of low 
on-treatment platelet reactivity (LPR) and associated bleeding risk with platelet testing 
may also gain importance besides the expanding use of more potent antithrombotic 
agents. Recent data suggest, that finding an optimal range in platelet inhibition (so 
called therapeutic window) would probably provide the best balance between ischemic 
and bleeding consequences and would maximize the neat clinical benefit of cardiac 
patients. 
 
Not only were ACS patients less extensively investigated in tailored antiplatelet 
therapy studies, but also the predictors of HPR in this cohort have not been adequately 
clarified to date. 
Almost a decade has passed, since a new point-of-care method, the multiple 
electrode aggregometry was introduced in clinical practice. Since then it has been used 
more and more extensively for successfully monitoring dual antiplatelet therapy, 
leading to establishment of a clinically predictive cut-off value [87]. Therefore, in our 
second study we aimed to identify simple clinical and easily accessible laboratory 
parameters that may be associated with HCPR defined by the established MEA 
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threshold in a large cohort of ACS patients (N=463). Thereafter, we developed a HCPR 
risk prediction model. 
Predictors of HCPR measured by Multiplate in patients with ACS – laboratory 
parameters  
Among several examined parameters, platelet count, CRP level upon admission, and 
current smoking proved to be predictors of HPR. According to our results, baseline 
platelet count, a routinely measured laboratory parameter, is a strong, continuous 
predictor of HPR, which is a novel finding to the best of our knowledge. Multiple 
electrode aggregometry measures platelet function in whole blood, where cell-cell 
interactions, micro-circumstances and the presence of a metal electrode surface could 
substantially influence platelet activation and aggregation. Platelet function measured 
by multiple electrode aggregometry has been reported to be dependent on interactions 
between platelets, red and white cells as compared to platelet function tests, where 
platelet aggregation occurs in cell purified, platelet rich plasma (e.g. light transmission 
aggregometry, LTA) [150,194]. Platelet aggregation values obtained by MEA have 
been reported to be significantly lower below the normal platelet count range [195], but 
were also described to be independent from thrombocyte count within the physiological 
limits in healthy, untreated patients [196]. Contrarily, we found an association even 
within the normal range after administration of 600 mg clopidogrel. Our patient 
population receiving dual antiplatelet therapy included patients with myocardial 
infarction mainly (95.9%) with high atherothrombotic burden, which was reported to be 
accompanied by elevated inflammatory markers [197]. Inflammatory conditions lead to 
increased platelet generation and turnover via IL-6 mediated thrombopoietin production 
and enhanced megakaryocyte proliferation [198], which may result in lower inhibitory 
effect of antiplatelet medication and higher in vitro platelet function even if platelet 
count is in the normal range. 
Not only was platelet count associated with HPR in ACS patients in the present 
study, but it was also an independent predictor of 30-day stent thrombosis even in a 
large, general PCI cohort [87]. Moreover, in that study, 30-day stent thrombosis was 
associated only with platelet reactivity measured by MEA and platelet count and no 
other clinical parameter was found to be predictive for ST. As some of the platelet 
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indices, like mean platelet volume and platelet distribution width were also reported to 
be associated with HPR measured by MEA in a general PCI cohort [199], we also 
examined the relation of mean platelet volume and HPR, but no correlation was found 
in the present study (data not shown).  
Our finding of baseline CRP level as predictor of HPR was in good agreement 
with that of other studies, where CRP was independently associated with HPR defined 
by different platelet function tests after elective PCI [137,150,200]. CRP level along 
with platelet count was also found to be higher in ACS patients with HPR than in those 
without measured by MEA in a recent study, however an independent association was 
not evaluated [174]. A direct relation between CRP levels and platelet count in humans 
has not been clarified yet; however, several possible mechanisms have been suggested. 
High CRP levels may lead to the activation of the clotting system [201] and increased 
thrombin generation may result in higher platelet activation. Inflammation indicated by 
elevated CRP level leads to down-regulation of several hepatic cytochrome P450 (CYP) 
isoenzymes involved in clopidogrel metabolization via inflammatory cytokines [202] 
which may result in impaired active metabolite production. Moreover, CRP is not only 
an inflammatory marker, but also known as a risk factor of cardiovascular disease and a 
predictor of recurrent ischemic events including stent thrombosis after PCI [203-206].  
Clinical predictors of HCPR 
According to our results, cigarette smoking was inversely associated with HCPR, 
further expanding the observation called the “smokers’ paradox”. This finding goes 
along with previous studies where smoking was also inversely related to HCPR defined 
by VerifyNow P2Y12 assay [137,139] and light transmittance aggregometry [147]. 
Smoking is known to be an inducer of the CYP1A2 hepatic enzyme [207], which is also 
involved in the conversion of clopidogrel. Increased CYP1A2 enzyme activity may lead 
to enhanced active clopidogrel metabolite generation and more expressed clopidogrel 
pharmacokinetic and pharmacodynamic effects [148]. Moreover, according to a meta-
analysis of major randomized clinical trials, the clinical benefit of clopidogrel therapy in 
reducing cardiovascular events was primarily seen in active smokers whereas the 
treatment effect was less favorable in non-smokers [208]. On the other hand, bleeding 
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risk was increased in clopidogrel treated current smokers compared to non-smokers 
[209]. 
Notably, none of the other numerous examined clinical and laboratory factors 
were associated with HPR, although platelet reactivity, mostly as a continuous variable, 
has been affiliated with several clinical parameters in a number of previous studies. The 
most important such factors are age, female gender, BMI, diabetes mellitus, renal 
failure, left ventricular function, acute coronary syndrome, some drug-drug interactions 
inhibiting the CYP2C19- and CYP3A4 enzymes [38,142,210], and in studies with 
whole blood platelet function tests, also leukocyte count [150,211]. The initial 
observations that raised concern of a potential interaction between PPIs and clopidogrel 
derived from in vitro studies showing that omeprazole-clopidogrel co-administration 
resulted in reduced active clopidogrel metabolite level and decreased in vitro platelet 
aggregation values, while pantoprazole had less of an interaction with clopidogrel [212]. 
However, the debated impact of this interaction on clinical outcome is not supported 
with data from randomized controlled trials [213,214]. In our in vitro study, we did not 
observe any correlation between HPR and PPI therapy (p=0.4). This might be explained 
by the almost exclusive use of pantoprazole and the originally high rate of PPI 
administration in our patient population. 
With respect to other clinical parameters, associations with platelet aggregation 
as a continuous variable were expansively observed previously, though their roles as 
independent predictors of a clinically derived HPR were conflicting or were limited to a 
certain method or stable CAD population [141,150,215,216]. The relatively low number 
of identified predictors despite the large number of investigated variables in the present 
study could reflect inappropriate sample size and might also be responsible for the 
moderate distinctive capacity of the risk prediction model (see below).  
Today, several point-of-care methods are available to measure platelet function 
in cardiac patients being on P2Y12 inhibitor therapy (Verify Now, Multiplate, and 
Plateletworks). Yet, none of them has been shown to be more accurate than the others. 
Importantly, distinct platelet function tests (including both the point-of-care and the 
more labor-intensive methods, such as the LTA or the vasodilator-stimulated 
phosphoprotein phosphorylation test) analyze and reflect different aspects of 
physiological platelet activation and aggregation; hence factors associated with HPR 
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defined by distinct methods might be heterogeneous as well. Therefore, it is unlikely 
that predictors of HPR might be uniformly applicable and they should always be 
evaluated in the context of a certain method. 
Rate of high on-clopidogrel platelet reactivity measured by MEA 
We found a relatively low rate of high on-clopidogrel platelet reactivity (16.0%) in an 
ACS patient cohort compared to previous literature, where HPR rate was reported 
within a very broad range depending on the applied platelet function test, threshold of 
HPR, and investigated patient population [125]. Considering the time lag between 
clopidogrel loading and MEA testing in our study (which is a frequently used time 
frame), aggregation units most likely reflected the effect of a single 600 mg clopidogrel 
loading dose, potentially explaining our low HPR rate. The consensus cut-off used in 
our study (>46 U) was also based on aggregation values of patients after clopidogrel 
600 mg loading dose [87] which may substantially differ in variability and in 
distribution from that of patients being on 75 mg maintenance therapy. It must be noted 
that when a more expressed or maximal drug effect is hypothesized, platelet inhibition 
may be less variable and the effect of different influencing factors might be less 
pronounced. Therefore, presence of HPR in the maintenance phase could be associated 
with more diverse variables [150], which might have an important effect on the long 
term efficacy of antiplatelet therapy. 
Risk prediction model for HCPR  
In our study, a risk prediction model of HCPR was built with the help of the identified 
predictors such as PLT count, CRP level and current smoking. Based on internal 
validation, the model proved to be only moderately optimistic, however its 
discriminative capacity was modest (AUC=0.665 and optimism corrected AUC=0.653). 
To achieve higher predictive power, identification of further potential predictors might 
be needed in the future. Though, with the help of the presented model, we could 
sufficiently classified patients into clearly separated low-, intermediate- and high risk 
categories. High-risk patients had more, than a fourfold increase in post-test probability 
of HCPR, than patients with low risk (8.7% vs 35.7%). Notably, the discriminative 
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capacity of our score was similar to that of found in other studies, where HPR risk 
prediction models were developed. Importantly, in these studies platelet function 
measurements were also timed 6-24 hours after 600 mg clopidogrel loading, though 
LTA was used to assess residual platelet aggregation. In the PREDICT-score, the 
authors included five clinical parameters used in a dichotomous fashion (namely age>65 
years, left ventricular dysfunction, renal failure, diabetes mellitus, and acute coronary 
syndrome) and composed a cumulative score (ranging from 0-9). Patients in the highest 
stratum (score 7-9) had 3.3 times higher probability to have HPR, than patients with a 
score of 0. Moreover, higher residual platelet aggregation values were associated with 
higher adverse event rates. Similarly in the PREDICT-STABLE score, where only 
elective PCI patients were included, the score was composed of five dichotomously 
treated clinical parameter (age>65 years, left ventricular dysfunction, renal failure, 
diabetes mellitus, and high BMI) to compose a score ranging from 0-9. The ratio of 
HPR increased gradually with score levels (14% vs 43.3% in the lowest and highest 
stratum) and 12 month MACE was also associated with PREDICT-STABLE score 
(3.4% vs 10.3% between low and high score levels). Unfortunately, due to feasibility 
reasons, we could not link follow-up and clinical outcome data to HPR values in our 
study, therefore association of identified predictors and HPR with recurrent ischemic 
events could not have been analyzed. However, parallel evaluation of the risk prediction 
model for HPR and for clinical outcomes would provide further valuable data. 
One of the major concerns regarding platelet function testing is their variable, 
but generally low positive predictive value. However, PPV is a diagnostic test statistic 
feature along with sensitivity, specificity, accuracy, and ROC curve c statistic. Platelet 
function testing can be assessed as either a diagnostic or a prognostic tool. It may be 
evaluated for its diagnostic performance in measuring the antiplatelet effect of a P2Y12 
inhibitor. Regarding this aspect, PF tests can be used to provide precise diagnostic 
evidence of P2Y12 inhibition [217]. However, the often challenged positive predictive 
value of platelet function testing depends on the prevalence of HPR in the population to 
be tested, thus limiting the measurement to those at high risk for HPR might increase 
the test’s positive predictive value. On the other hand, PPV should not be used in the 
assessment of the predictive value of platelet function testing, as the prevalence of the 
clinical event that PF testing is expected to predict – namely stent thrombosis – is 
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generally low (1-2%) in the studied cohorts. Instead, in evaluating prognostic 
performance of PF testing, risk assessment tests should be used, which describe the 
multiplicative risk of the condition or hazard (using odds ratios and hazard ratios). 
Importantly, these tests are used to assess risk, not to diagnose whether or not a future 
event will occur. Thus, it is possible, that some patients with high risk will not 
experience the certain event, while patients in low risk stratum will suffer from it. 
Moreover, a statistically significant association does not necessarily mean a biologically 
significant association. Therefore, further statistical techniques are usually needed to 
verify that the test has an additive value to other established risk scores and it may 
improve the overall risk assessment  (e.g. change in the ROC curve c statistic, or using 
net reclassification improvement (NRI) and integrated discrimination improvement 
(IDI) tests) [218]. Such additive prognostic value of PF testing has been nicely 
demonstrated in the large clinical trials. In the POPULAR study, addition of HPR to 
established clinical risk scores for predicting clinical outcome resulted in significant 
increase of the ROC c-statistic value. In the ADAPT-DES study, analysis of the NRI 
and IDI showed that platelet reactivity measured by VerifyNow was able to reclassify 
the risk of developing both ischemic and bleeding events beyond the baseline clinical 
characteristics of the patients. 
 
Based on the foregoing, PF testing may have an important role in risk 
assessment and identification of patients who may profit from antiplatelet therapy 
intensification. Importantly, the prevalence of HPR has been shown to be higher in ACS 
patients compared to a stable CAD cohort [81], representing higher atherothrombotic 
risk of these patients. Since HPR rate proved to be moderate (16%) even in the ACS 
cohort in our study, identification of patients with high risk for HPR by the presented 
clinical model might enable more purposeful use of platelet function testing. By limiting 
the target population to be tested with the help of risk prediction models, HPR risk 
assessment might potentially contribute to a more conscious design of clinical trials 
investigating the effect of platelet function test guided antiplatelet therapy and a more 
purposeful use of platelet function testing. Our results also suggest that platelet function 
is a well determinable and modifiable clinical factor even in the acute presentation of 
CAD and its in vitro monitoring may contribute to select the adequate individual 
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therapy of a cardiac patient in a complex clinical setting. Applying proper therapy at the 
individual level may be the fair way to improve the clinical outcome of a large 
population. 
In conclusion, to make a final judgement about the role of platelet function 
testing after percutaneous coronary intervention, further carefully designed large scale, 
randomized clinical trials are needed. Study design should be particularly deliberate 
considering antiplatelet loading and maintenance doses (for sake of comparability), 
timing of platelet testing (loading vs maintenance dose effect), the applied platelet 
function test, and should use predetermined cut-off values, therapy intensification 
algorithms and follow-up period as well as standard, well defined clinical end points.  
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6. CONCLUSIONS 
 
6.1. We found an increased level of ADP induced platelet reactivity measured by light 
transmission aggregometry in patients with myocardial infarction compared to those 
with stable coronary artery disease, representing heightened atherothrombotic risk of the 
acute patient cohort. 
 
6.2. In patients with myocardial infarction, initial, clinical risk profile but not platelet 
function test guided clopidogrel dose doubling resulted in the same inhibitory potency 
as the standard dose clopidogrel in patients with expectedly lower risk for high on-
treatment platelet reactivity. 
 
6.3. The ratio of patients, who had high on-clopidogrel platelet reactivity even on high 
dose clopidogrel (real non-responders) was significantly higher in the myocardial 
infarction group, suggesting that this patient cohort with higher thrombotic risk might 
benefit from prospective platelet function testing, especially in view of reported 
prevalence of high on-treatment platelet reactivity even beside the novel antiplatelet 
agents. 
 
6.4. Therapy modification resulted in effective platelet inhibition in majority of the 
patients, according to in vitro testing. The potent inhibitory effect of therapy conversion 
proved to be stable during 12 month follow-up. 
 
6.5. Among patients on clopidogrel therapy, appearance of new high on-clopidogrel 
platelet reactivity was observed during 12 months, irrespective of applied clopidogrel 
dose or representing clinical syndrome. This may suggest the vulnerability of 
clopidogrel effect in the long term, and highlights the potential significance of repeated 
evaluation of antiplatelet therapy. 
 
6.6. We analyzed the association of a wide range of clinical and laboratory parameters 
with high on-clopidogrel platelet reactivity measured by multiple electrode 
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aggregometry in an acute coronary syndrome cohort and identified elevated platelet 
count and CRP level upon admission and a non-smoking status as predictors. 
 
6.7. We developed and internally validated a risk score for high on-clopidogrel platelet 
reactivity, which enabled successful classification of the patients into low, intermediate 
and high risk strata. Patients with the highest risk had more than a fourfold increase in 
post-test probability of high on-clopidogrel platelet reactivity compared to those with 
low risk. Such a risk assessment of high on-treatment platelet reactivity might enable 
more targeted use of platelet function testing to identify patients who may benefit from 
therapy intensification. 
 
6.8. With recent reclassification of on-treatment platelet reactivity into low, optimal and 
high categories, platelet function testing may be used to find a therapeutic window to 
optimize the balance of ischemic and bleeding consequences in patients on dual 
antiplatelet therapy. 
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7. SUMMARY  
 
The great success of percutaneous coronary intervention in the treatment of CAD was 
enabled by induction of dual antiplatelet therapy to prevent thrombotic events. Due to 
variable platelet inhibition on clopidogrel therapy, it has been replaced by more potent 
P2Y12 inhibitors in invasively treated patients with acute coronary syndrome (ACS). 
Since with the use of these inhibitors bleeding events became more frequent, patients 
with SCAD and ACS patients at high risk for bleeding remained subject to clopidogrel 
treatment. High on-clopidogrel platelet reactivity (HCPR) is known as a predictor of 
recurrent ischemic events. Therefore, screening patients with HCPR and optimizing 
individual antiplatelet therapy might improve clinical outcome.  
The aim of our study was to identify patients with HCPR and to induct an 
intensified antiplatelet therapy with a 12 months follow-up in patients with MI and 
SCAD. We also intended to identify predictors of HCPR and to develop a risk 
prediction model in an ACS cohort. We found that platelet reactivity and the rate of 
HCPR even on elevated clopidogrel dose is higher in patients with MI than in those 
with SCAD after PCI. HCPR can be functionally overcome by switch of therapy. 
Platelet inhibition in patients on dual antiplatelet therapy alternates over time and an 
incidence of new HPR irrespectively of antiplatelet therapy modification is observed in 
both patient groups. We found that platelet count, C-reactive protein level on admission, 
and non-smoking status were associated with HCPR. With the help of these 
determinants, a risk prediction model has been developed and internally validated. In 
summary, patients with MI may benefit from prospective platelet function testing 
because of higher thrombotic risk represented by elevated platelet aggregation values 
and higher rate of HCPR even on elevated clopidogrel dose. Moreover, therapy 
alteration leads to efficient platelet inhibition in majority of the MI patients. The risk 
prediction model with simply available parameters might help to identify individuals at 
high risk for HCPR and risk assessment might contribute to the more targeted use of 
platelet function testing. HCPR is a well detectable, predictable and modifiable 
parameter even in the acute presentations of CAD with high thrombotic risk and thus 
platelet function testing might contribute to improving the clinical outcome of this 
patient cohort.  
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8. ÖSSZEFOGLALÁS 
 
A perkután koronária intervenció (PKI) terápiás sikerét az iszkémiás szívbetegség 
kezelésében a kettős trombocitagátló kezelés bevezetése tette teljessé a trombotikus 
szövődmények gyakoriságának csökkentésével. A clopidogrel helyét - a trombocitagátló 
potenciál nagyfokú varianciája miatt - hatékonyabb trombocitagátló szerek vették át az 
invazívan kezelt akut koronária szindrómás betegek terápiájában. Azonban az új szerek 
mellett észlelt magasabb vérzési rizikó miatt a betegek egy része nem részesülhet az 
általuk nyújtott terápiás előnyökben. A terápia melletti magas trombocita reaktivitás 
(MTR) és a kedvezőtlen klinikai kimenetel összefüggését felismerve felmerült, hogy a 
trombocita funkció mérése és MTR esetén a trombocitagátló terápia intenzifikálása 
javíthatná a betegek klinikai kimenetelét. Vizsgálataink célja a MTR gyakoriságának 
trombocita funkciós teszttel történő felmérése, a trombocitagátló terápia intenzifikálása 
és utánkövetése volt elektív és miokardiális infarktus (MI) miatt PKI-ra kerülő 
betegekben. Vizsgáltuk továbbá a MTR-t meghatározó klinikai és laboratóriumi 
tényezőket egy rizikóbecslő modell kifejlesztése céljából. Eredményeink alapján 
infarktusos betegekben magasabb trombocita reaktivitás észlelhető az elektív 
csoporthoz képest. Az infarktus csoportban az emelt dózisú clopidogrel kezelés mellett 
észlelt valódi non-reszponzió aránya szignifikánsan magasabb volt. A terápiamódosítás 
a betegek többségében hatékony trombocita gátláshoz vezet az in vitro mérések alapján. 
12 hónapos utánkövetés során a betegek egy részében terápiamódosításhoz nem 
köthető, újonnan megjelenő MTR-t észleltünk. A MTR meghatározó tényezőit 
vizsgálva a felvételi trombocita számot és CRP szintet, valamint a nemdohányzó 
státuszt azonosítottuk prediktorként, melyek felhasználásával egy MTR rizikóbecslő 
modellt építettünk és sikeres rizikó stratifikációt végeztünk. Eredményeink alapján MI-
ban a magasabb trombotikus rizikót jelképező trombocita hyperreaktivitás, a clopidogrel 
valódi non-reszponzió gyakoribb előfordulása és a trombocita reaktivitás 
terápiamódosítás általi befolyásolhatósága miatt a trombocita funkció prospektív mérése 
ezen betegekben kifejezett előnyökkel járhat. Akut koronária szindrómában a MTR 
rizikója néhány egyszerű paraméter segítségével megbecsülhető, a stratifikáció 
segítséget nyújthat a trombocita funkciós tesztek célzottabb felhasználásában és a 
terápia intenzifikálásából leginkább profitáló betegek azonosításában. 
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